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E-CIGARETTES AND SMOKING CESSATION: ECONOMIC IMPACT ON CURRENT 
SMOKERS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
By Anal Shah, MS, PhD 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University  
Virginia Commonwealth University, 2017  
Advisor: David Holdford, PhD Professor, Department of Pharmacotherapy and 
Outcomes Science 
 
Introduction: 
Awareness and usage of Electronic cigarettes (e-cigs) among smokers have increased 
rapidly over the past few years, majorly in quitting smoking. The main objectives for this 
study were:  1) To estimate the prevalence and study sociodemographic predictors for 
e-cigs use among individuals with Chronic Obstructive Pulmonary Disease (COPD). 2) 
To examine the predictors and estimate the total healthcare costs among current 
smokers with COPD. 3) To estimate the economic impact of adopting e-cigs as a 
smoking cessation tool among smokers with COPD.  
 
xv 
 
Methods:  
The National Health Interview Survey data from the year 2014 was utilized to estimate 
the prevalence and identify sociodemographic predictors associated with e-cigs use 
among COPD adult population. Total healthcare costs and sociodemographic and 
clinical predictors among current smokers with COPD were estimated using the Medical 
Expenditure Panel Survey data from the year 2012-2013.  
Economic impact for adoption of e-cigs was obtained by developing an epidemiological 
cohort-Markov model from a societal perspective over the period of 5-year. The targeted 
population was smokers with COPD and willing to quit smoking. Smoking abstinence for 
e-cigs was compared with Varenicline, Bupropion, and Nicotine Replacement therapy. 
Outcomes evaluated were the 1-year and accumulated 5-year total healthcare costs 
savings associated with e-cigs over other options. 
Results:  
Among individuals with COPD, 8.65% and 24.37% were current and ever e-cig users 
respectively. Current e-cigs use was found to be associated with individuals who have 
tried quitting smoking in the past (OR: 2.0; 95%CI: 1.05, 3.97). Adjusted total healthcare 
costs per patient/year among smokers with COPD were found to be higher by $1,811 in 
comparison to non-smokers with COPD. The adoption of e-cigs among COPD smokers 
can have a positive impact on the healthcare budget and can lead to healthcare cost 
savings of $37.71 million over the period of 5-year. Furthermore, a positive impact on 
budget were found among women and individuals with age 65 & above.  
 
xvi 
 
Conclusion:  
E-cigs may be beneficial to the current US healthcare system if adopted as a smoking 
cessation tool among COPD individuals. However, uncertainty associated with product 
safety, efficacy and adherence for cessation warrants further studies and evaluation. 
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Chapter 1: Introduction 
Chronic Obstructive Pulmonary Disease  
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease arising 
due to obstruction in the lung airways that can result into having shortness of breath and 
cough as its chief symptoms.1 It is mainly characterized as having emphysema and 
chronic bronchitis and in some conditions it includes asthma as well.2 Emphysema, 
categorized as a type A COPD, is a diease of the lung wherein alveolis that are 
responsible for the exchange of carbon dioxide and oxygen are damaged resulting into 
the loss of lung tissue functioning.3 This can lead to experiencing shortness of breath, 
having cough and wheezing. In the majority of people, symptoms of emphysema 
progress slowly.4 Chronic bronchitis, categorized as a type B COPD, is a lung disease 
arising due to an inflammation of the lung airways leading to the development of cough, 
that can last anywhere from 3 months to 2 years in a row, along with the frequent 
manifestation of viral and bacterial infections.2,3 Other common symptoms for an 
individual with COPD involves experiencing chest tightness, fatigue, and a chronic 
cough. These symptoms gets worse over time where patients can experience muscle 
loss, can have morning headaches, or can develop bluish or greyish color below the 
fingernails due to less supply of oxygen levels in the blood.5 Treatment for COPD will 
depend on the condition and severity of the disease and treatment choices will involve 
the use of medications such as long- or short-acting bronchodilators, steroids, 
antibiotics, along with using other treatment options such as oxygen therapy, 
pulomonary rehabilitation program, or performing surgeries such as lung volume 
reduction, doing lung transplant or bullectomy.6  
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According to the Global Initiative for Chronic Obstructive Lung Disease, it defines COPD 
into four different stages on the basis of spirometry results from the lung fuction test.7 
This test estimates the amount of air an individual can blow out in one second, also 
known as Forced Expiratory Volume (FEV1). Table 1 below depicts different stages for 
COPD according to the FEV1 levels. As an individual progresses towards different 
stages of COPD, breathing and airflow becomes more dififcult. COPD staging can help 
patients to better understand their disease condition and predict life expectancy, while 
for physicians it can help them make better treatment recommendations.7  
Table 1: COPD staging by GOLD classification and FEV1 levels 
GOLD stages7 COPD term FEV1 levels 
Stage I Mild COPD FEV1≥ 80% normal 
Stage II Moderate COPD FEV1 50-79% normal 
Stage III Severe COPD FEV1 30-49% normal 
Stage IV Very Severe COPD FEV1 <30% normal, or <50% normal 
with chronic respiratory failure 
present 
COPD epidemiological facts 
In 2004, 3 million deaths occurred globally due to COPD where 90% of them were from 
low and middle income countries.8 World Health Organization (WHO) has projected 
COPD to be the third most leading cause of death by 2030.8 Global burden for COPD is 
expected to increase in future years due to a globally aging population and a continuous 
exposure to risk factors such as air pollution and smoke.9,10 In the United States, the 
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Centers for Disease Control and Prevention (CDC) ranked COPD as the third most 
leading cause of death and disability in 2014.11 Nearly 15 million US adults were 
diagnosed with COPD in 2014 and prevalence was found to be varying by state. 
Despite such high prevalence, it remains undiagnosed or untreated in nearly half of the 
patient population.12 COPD rates were found to be higher in individuals over age the 
age of 65 years, in women, in non-Hispanic white population, those who are 
unemployed, divorced, widowed or separated, are current or former smokers and have 
the history of asthma.11  
COPD and economic burden  
COPD is a major driver of avoidable healthcare costs.13 It causes long-term disability, 
early deaths and is an important issue affecting employees health and work-
productivity.14,15 In 2010, the National Heart, Lung, and Blood institute estimated direct 
healthcare costs due to COPD as $29.5 billion, where $13.2 billion accounted for 
hospital care costs, $5.5 billion were for physician services and $5.8 billion were for 
prescription drugs.16 The indirect costs was around $20 billion and the number of 
productive days lost due to suffering from COPD was higher than any other chronic 
conditions.17,18 An adult with COPD spends on an average $6,000 more to healthcare 
than an adult without COPD.19 Healthcare costs also vary by COPD severity stages as 
an individual in later stage incurs higher medical costs than an individual with COPD in 
an early stage. The average per patient per year direct cost for patients with stage I, 
stage II and stage III COPD were $1681, $5037 and $10,812 respectively.20 
Hospitalization was identified as one of the most significant and contributing cost 
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variable for all the stages of COPD. By the year 2020, CDC has projected that medical 
care costs for COPD will be higher than $90 billion signifying a substantial and a 
significant economic burden to the individuals and society.21  
COPD and Smoking  
Several risk factors responsible for the development and progression of COPD include 
tobacco smoke, air pollutants, occupational dusts and chemicals, genetics, history of 
childhood respiratory infections, socio-economic status and exposure to second hand 
smoke (SHS).22 However, the key factor responsible for the development of this disease 
is smoking tobacco where for all those individuals who have been diagnosed with 
COPD, almost 90% of them have smoked tobacco.23 Tobacco smokers are nearly 12 to 
13 times at higher risk of death from COPD than those who are non-smokers.24 
Individuals with a family history of COPD are at a higher risk to develop this disease if 
they smoke tobacco.  
Tobacco smoking itself is the single largest preventable cause of disease and death in 
the United States leading to more than 480,000 deaths every year and more than 
41,000 of these deaths are due to second hand smoke (SHS) exposure.25 In 2014, an 
estimated 40 million US adults aged 18 years or older were current smokers.26 
Prevalence of current smokers differs by age and gender. The percentage of people 
who were current smokers was found to be higher in working adult population aged 18-
64 years (54.7%) in comparison to those with age 65 and over (8.5%). Similarly, 
prevalence of current smoking was higher in males (18.8%) in comparison to females 
(14.8%) in the US for the same year.25 Tobacco smokers are 2-4 times at a higher risk 
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to develop coronary heart disease, 2-4 times at a higher risk to develop stroke and 
nearly 25 times at a higher risk to develop lung cancer. It affects overall health, 
increases absenteeism from work and possess higher healthcare utilization and cost.27 
Annual healthcare spending attributable to such smoking-related illness in adults was 
more than $300 billion per year, which includes $170 billion in direct medical care cost 
and $156 billion for productivity loss.  Hence, COPD patient population who are 
currently smoking tobacco possess not just high medical direct and indirect healthcare 
costs but are also at a higher risk to develop other smoking-related illness which can yet 
again have a huge economic burden to the individuals and the society.28 In order to 
lower such high medical care cost and sufferings due to COPD and smoking-related 
illness, clinicians are highly recommended to use the interventions that can help prevent 
tobacco smoking and can reduce clinical complications due to COPD, while patients are 
recommended not to smoke and seek medical advice from physicians for quitting 
tobacco smoke.29  
COPD and Smoking Cessation 
Several methods are utilized or recommended to help quit tobacco smoking. They 
include the use of either cold-turkey, behavioral counseling, Nicotine Replacement 
Therapy (NRT’s), prescribed medications such as Varenicline, Bupropion, or using the 
combination treatments which includes the mix of behavioral counseling along with 
prescribed medications.29 Amongst alternatives, the most frequently utilized and 
recommended are prescribed medications such as Varenicline or Bupropion, or over the 
counter medications such as NRT’s.30 However, these products have relatively less 
consumer attraction and product satisfaction.30,31 Possible reasons could be due to the 
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side effects associated with the use of these medicinal products. Other plausible 
reasons are medication costs, difficulty in adhering to the medications prescribed, and 
costs of seeing physician to receive a prescription. 
E-cigarettes and Smoking Cessation 
Electronic cigarettes (e-cigs), also known as electronic nicotine delivery system (ENDS), 
are battery operated devices that deliver nicotine to the users by heating a solution of 
nicotine, propylene glycol or glycerin, and flavoring agents into a gas for inhalation.32 
These devices were introduced into the US market in the year 2007 as an alternative to 
conventional tobacco smoke.33 They are manufactured to resemble tobacco cigarettes 
and are available with more than 500 different brands and 7700 unique flavors.34 Most 
e-cig devices a made of a cartridge, a heating device and a power source.32 Currently, 
four generations of e-cig devices are available in the market and each of them differs 
with respect to the device size and shape.32 As these devices resemble conventional 
tobacco cigarettes in its aesthetics, they are thought to simulate the behavioral 
experience of tobacco smoking. In addition, they deliver nicotine without the harmful 
chemicals and tar emitted by regular tobacco cigarettes.32 Since the introduction of 
these devices into the US market, their sales have grown (almost $1.5 billion dollars per 
year) and it is estimated that the sales may continue to rise by 24.4% per year until 
2018.35,36   These devices are marketed direct to consumers via television, internet and 
print advertisements as a healthier substitutes to tobacco smoke.37  
The CDC reported that the use of these devices among US adults has increased over 
years.38 In 2014, prevalence of e-cig users among the US working adult population was 
found to be 3.8% (5.5 million of 146 million people), where nearly 16.2% of these 
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estimates were current cigarette smokers.38 In another study done by McMillen et al., 
which assessed four year trends in e-cigs use among the US adults between the years 
2010 and 2013, percentages of people who were ever e-cig users increased from 1.8% 
to 13% while for current e-cig users these estimates increased significantly from 0.3% to 
6.8%.39   Recently, a new trend to consume these devices to quit tobacco smoking has 
been found where smokers are finding these devices helpful in helping them to quit 
smoking and are preferred more over medicinal products that are currently available in 
the market for smoking cessation.40,41 A household survey amongst US current smokers 
done in June 2011 had 70% of the respondents reporting to use e-cigs for helping them 
to quit smoking.35 Several clinical trials and systematic literature reviews have been 
published with the mixed results for its evidence related to efficacy of e-cigarettes use in 
smoking cessation amongst current smokers.42,43,44,45,46 
The use of e-cigs for smoking cessation is controversial amongst health experts where 
some question whether these devices are helping smokers in quit or whether they just 
serve as a gateway to start smoking. Experts in the UK are open promote the use of 
these e-cigs to help smokers in quitting, while experts in the US are less enthusiastic 
due to concerns about encouraging tobacco use among the younger population.47,48     
E-cigarettes and the U.S. regulations  
E-cigs were unregulated in the United States until May 5th, 2016, where the US FDA 
announced a ban on sales to anyone under age 18.49,50 Also, adults under 26 years are 
required to show their photo-id before making a purchase. In addition, e-cig producers 
will now be required to go through a lengthy registration and safety review process with 
the FDA to get their product approved along with other regulatory requirements such as 
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providing them product ingredient details (including potentially harmful additives), 
manufacturing process and evidence that the product is safe to consume. Any e-cig 
devices with different flavors will have to be registered seperately as a new product and 
this regulation applies to all vape shops as well that sell e-cigs with their own unique 
product flavors.49 Producers will have to get FDA approval for their products first before 
marketing them with any product labels that can claim as mild or light. Producers will 
also be restricted from giving out free samples for promotion. All e-cig manufacturers 
are expected to have registered with the FDA by August 8th, 2016. They will have up to 
2 years to sell their products while preparing for their FDA applications, and up to 1 
additional year till FDA reviews their submitted application.49  
Health experts believe that this law can either lay a new generation to the use of 
traditional cigarettes or can reduce the number of current smokers trying to use this 
device for quiting smoking.51,52  Furthermore, it is also believed that this new law is 
going to be tough for small producers as it will be challenging for them to meet the FDA 
deadlines for product registration along with the expenses that comes around with the 
litigation process. According to the American Vaping Association, new regulations will 
be prohibitively expensive to small producers as submitting a new application could take 
somewhere around 1700 hours and more than $1 million dollars.53,54 Despite this new 
regulation, manufacturers and proponents are actively promoting e-cig products for its 
use in smoking cessation through paid press releases and online via social media 
through Facebook, Twitter, and YouTube.37 Some promote misleading claims regarding 
the effectiveness of their devices.37 Others target pregnant women by claiming that use 
of e-cigs in pregnancy is safer and healthier than conventional tobacco products.54 The 
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lack of evidence about effectiveness and safety of e-cigs has led the US government be 
cautious in supporting its use in smoking cessation.  
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Chapter 2: Literature review 
2.1: Literature Review 
Tobacco use is a major risk factor in the development of chronic diseases such as 
cancer, stroke, heart disease, lung diseases, COPD, and diabetes. It can harm almost 
every organ of the body.25 Nevertheless, its use is common throughout the world. 
Global deaths due to use of tobacco are nearly 6 million per year; projected to rise to 8 
million deaths per year by 2030.55 It is a major cause of preventable death, where those 
who smoke live 10 years less on average than those who do not smoke.56  Quitting 
smoking is associated with significant health benefits.55  
Several therapies are available in the market for smokers to help them in reducing or 
quitting tobacco use. The United States Public Health Service recommends the use of 
first-line pharmacotherapies such as nicotine replacement therapy (NRT), Bupropion, 
and Varenicline for smoking cessation.57 These therapies have established safety and 
efficacy profile to treat tobacco dependence and are approved by US-FDA for cessation 
of smoking. These pharmacological aids make it easier for a smoker to quit the use of 
tobacco by helping users in reducing the symptoms of nicotine withdrawal.57  
Bupropion was approved by the US FDA in 1997 as a smoking cessation 
pharmacotherapy drug that is available only by prescription.58 It exerts its main effect 
through blocking the reuptake of dopamine and noradrenaline along with the presence 
of little serotonergic effect. It is available as an extended release anti-depressant pill 
that helps in reducing symptoms associated with nicotine withdrawal. Treatment 
duration for such therapy can be anytime between 7-weeks and 12- weeks.58  
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In 2006, the US FDA approved another prescription pharmacotherapy Varenicline 
tartrate (available as Chantix) for its use in smoking cessation for the course of 12-
weeks.59 It is a partial agonist at the alpha-4 beta-2 subunit of the nicotine acetylcholine 
receptor where by binding to this receptor it helps in reducing symptoms associated with 
nicotine withdrawal. It also blocks nicotine from the smoke to bind with this receptor and 
thereby it reduces the dependence to nicotine. This drug is very well tolerated, has 
better efficacy profile and hence makes it a valuable option among smokers for quitting 
smoking.59  
Currently, there are three different Nicotine Replacement Therapies (NRT’s) available in 
the US market as over the counter (OTC) medications.60 These include lozenges, 
chewing gum and transdermal patches. NRT’s deliver nicotine at the sub-optimal level 
in the brain above which is associated with withdrawal. Hence it helps smokers in 
overcoming nicotine withdrawal symptoms. Long-acting Nicotine patches are prescribed 
primarily to control long-term abstinence, while rapidly-acting Nicotine lozenges/gums 
are provided to help relieve rapid acute cravings and withdrawal symptoms. The choice 
for this rapid-acting will depend on patient comorbidities and their preferences. Overall, 
these products are considered to be safe for patients and are used more commonly 
among other available alternatives for quitting smoking.60  
Despite the availability of these pharmacotherapies that have shown great clinical 
response to achieving smoking cessation, these treatments however lack the behaviour 
and sensory aspects of smoking among smokers wanting to quit.40 E-cigarettes address 
this limitation along with offering a novel approach to smokers to use these devices for 
cessation. E-cigs can deliver a dose of nicotine that can be decreased gradually to a 
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placebo level, and can provide satisfaction to the smokers as it mimics smoking 
behaviour. They are cheaper than regular tobacco, can be used for long-term and can 
provide nicotine without involving those 7000 chemicals that are known to have cause 
cancer.41 Several studies have tried to evaluate the effect of these devices in smoking 
cessation over short and long-term along with the evaluation of side effects.  
Hence, a comprehensive literature search of MEDLINE through PubMed and Google 
Scholar was performed to review articles that analyzes the effect of e-cigarettes in 
smoking cessation for a minimum period of 6-months. Search terms used were 
[“Electronic cigarettes” OR “e-cigarette” OR “e-cigs” OR “Electronic nicotine delivery”] 
AND [“Smoking cessation” OR “Quit smoking” OR  
“Smoking abstinence” OR “Smoking reduction”]. Cited articles were retrieved from the 
original articles to include additional research articles. Articles that were included for 
review were the ones that were conducted in humans, among adults currently smoking, 
have investigated smoking cessation or abstinence as a primary outcome, outcomes 
that were measured for at least 6-months, published in English and with the study 
design as randomized controlled trials, cross-sectional studies, cohort studies or case-
control studies. 
On the basis of this search criteria, 19 studies were found that evaluated the effect of e-
cigarettes for its use in smoking cessation for the minimum period of 6-months. Table 2 
summarizes them all on the basis of study design, sample size included, participants 
characteristics, study intervention and smoking cessation outcome. 
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Table 2: Literature review articles – E-cigs & Smoking Cessation 
Source Study participants Sample 
size 
Intervention vs. comparator Smoking cessation outcome 
Randomized controlled trial  
Bullen et 
al. 2013  
(ASCEND 
trial)42  
Current smokers from Auckland, 
New Zealand, 18 years and older, 
with the intention to quit smoking 
657 Three groups compared parallel:  
Group A:B:C: 16 mg nicotine e-
cigs; 21 mg nicotine patch; 
placebo e-cigs 
Verified continuous smoking 
abstinence rate at 6 months: 
7.3% (group A) vs. 5.8% (group 
B) vs. 4.1 %( group C).  
≥ 50% reduction in cigs 
smoked/day at 6 months: 57% 
(group A) vs. 41% (group B) vs. 
45 %( group C). 
Caponnetto 
et al. 2013 
(ECLAT 
trial)43  
Current smokers from Catania, 
Italy, between 18 and 70 years 
older, with the intention to quit 
smoking 
300 
 
Three groups compared parallel:  
Group A:B:C: 7.2 mg nicotine e-
cigs; 7.2 + 5.4 mg nicotine e-cigs; 
placebo e-cigs 
Verified continuous smoking 
abstinence rate at 12 months: 
13% (group A) vs. 9% (group B) 
vs. 4 %( group C).  
≥ 50% reduction in cigs 
smoked/day at 6 months: 13% 
(group A) vs. 9% (group B) vs. 4 
%( group C). 
Adriaens et 
al. 201461 
Current smokers from Leuven, 
Belgian, not intending to quit 
smoking 
51 Three groups compared parallel:  
Group A received the Joyetech e-
GO-C second-generation e-cigs; 
group B received the Kanger T2-
CC second-generation e-cigs, 
while group C received no 
treatment at baseline. For both 
groups; A and B, participants were 
provided 30 ml bottles of tobacco-
flavored e-liquid with 18mg/ml of 
nicotine 
Verified continuous smoking 
abstinence rate at 8 months: 19% 
(total for both group A and B) vs. 
25% (group C).  
Combined smoking reduction and 
smoking abstinence among e-cig 
users at 8-months: 44% 
Prospective cohort study with intervention 
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Polosa et 
al. 201162 
Regular smokers, 18-60 years 
old, from Catania, Italy,  not 
intending to quit smoking 
40 Participants were invited to use 
popular e-cig brand containing 7.4 
mg nicotine as its dose strength 
Self-reported continuous smoking 
abstinence rate at 6-, 18- and 24-
months: 23%, 15% and 13% 
respectively. 
≥ 50% and ≥80% reduction in 
cigs smoked/day at 6 months: 
32.5% and 12.5% respectively 
Caponnetto 
et al.201363  
Regular smokers with 
schizophrenia, from Catania, 
Italy,  not intending to quit 
smoking, 
14 Participants were invited to use 
popular e-cig brand containing 7.4 
mg nicotine as its dose strength 
Self-reported continuous smoking 
abstinence rate at 12-months: 
14.3%. 
≥ 50% reduction in cigs 
smoked/day at 12 months: 50% 
Ely J et al. 
201364 
Current smokers, residing in 
Moffat county, Colorado, 
motivated to quit 
44 Provided structured smoking 
cessation program for 6-months 
which was based on the ‘5As’ and 
the transtheoretical model to treat 
tobacco use and dependence 
Self-reported continuous smoking 
abstinence rate at 6 months: 44% 
Polosa et 
al. 2014i65 
Regular smokers, from Catania, 
Italy,  not intending to quit 
smoking 
40 Participants were invited to use 
popular e-cig brand containing 7.4 
mg nicotine as its dose strength 
Self-reported continuous smoking 
abstinence rate at 24 months: 
12.5% 
≥ 50% reduction in cigs 
smoked/day at 6, 18 and 24 
months: 25%, 27.5% and 27.5% 
respectively 
≥ 80% reduction in cigs 
smoked/day at 6, 18 and 24 
months: 1%, 7.5% and 15% 
respectively 
Polosa et 
al. 2014ii66 
Regular smokers, 18-60 years 
old, from Catania, Italy,  not 
intending to quit smoking 
50 Participants were invited to use 
popular e-cig brand containing 9 
mg/ml nicotine as its dose strength 
Self-reported continuous smoking 
abstinence rate at 6 months: 36% 
≥ 50% and ≥80% reduction in 
cigs smoked/day at week-24: 
30% and 14% respectively 
Pacifici et 
al. 201567 
Current adult smokers, 18-63 
years old,  not intending to quit 
smoking, have never tried quitting 
34 Provided commercially available e-
cigs device. Medical training and 
assistance for e-cigs use were also 
Self-reported continuous smoking 
abstinence rate at 12 months: 
53%  
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tobacco use, never tried any 
smoking cessation therapies 
provided along with behavioral 
support 
Polosa et 
al. 201568 
Adult smokers (≥ 18), making first 
purchase at participating local 
vape shop in Catania, Italy 
71 Participants motivated to use e-
cigs along with providing 
instructions on e-cigs use 
Self-reported continuous smoking 
abstinence rate at 6- and 12-
months: 42% and 41% 
respectively 
Aggregated smoking reduction 
and abstinence at 12-months: 
66.2% 
Prospective cohort study with no intervention 
Etter et al. 
201444 
Longitudinal online survey among 
participants registered online, age 
18 and over, have provided their 
email address for follow-up, daily 
e-cig users. Participants 
registered were from US, UK, 
France, Switzerland, and other 
countries. 
773 -- Complete self-reported cessation 
at 1- and 12-months: 22% and 
46% respectively 
Reduction in daily cigs smoked 
per day at 12-months: 10.5 
Grana et al. 
201469 
Longitudinal online survey among 
current smokers, recruited 
through Knowledge network 
panel, have used e-cigs in past 3- 
days even once 
949 -- Complete self-reported cessation 
at 12-months among regular 
smokers with and without e-cig 
use at baseline: 10% (9/88) and 
14% (119/861) respectively. 
 
Borderud 
SP et al. 
201470 
Current smokers, diagnosed with 
cancer, referred to the Tobacco 
Treatment Program at Memorial 
Sloan-Kettering Cancer Center, 
New York, using e-cig devices 
within 30-days prior to enrollment, 
motivated to quit 
1074 -- Complete self-reported cessation 
at 12-months: 14.5%  
Prochaska 
et al. 201471 
Adult current smokers, not 
motivated to quit tobacco, using 
e-cigs at baseline 
956 -- Complete self-reported cessation 
at 12-months: 21% 
Choi et al. 
201472 
Young adults, currently smoking, 
residing in Minnesota, never used 
1379 -- Complete self-reported cessation 
at 12-months: 11% 
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e-cigs at baseline, able to follow-
up at 1-year,  
Brown et 
al. 201445 
Current smokers, ≥ 18 years, 
smoked in past year, made at 
least one quit attempt either with 
e-cigs or NRT’s or without any 
aids. 
5863  Self-reported nonsmoking at > 26 
weeks for e-cigs, NRT’s and 
without any aid: 19.1%, 8.4% and 
16.7% respectively 
Brose LS et 
al. 201573 
Web-based online survey among 
current smokers, recruited 
through Ispos MORI, have used 
e-cigs at baseline 
4064 -- Complete self-reported cessation 
at 12-months: 8% 
% attempted to quit in past 1 
year: 46% 
 
 
Al-Delaimy 
et al. 201574 
Telephone based survey among 
California smokers, between 18 
and 59 years old, have used e-
cigs at both baseline and follow-
up, with the intention to quit 
smoking 
 -- Complete self-reported cessation 
at 12-months among ever e-cig 
users and among never e-cig 
users: 5% and 10.5% 
respectively 
Manzoli et 
al. 201575 
Current smokers, between 30 
and 75 years of age, used any 
type of e-cigs and inhaling at 
least 50 puffs weekly for past 6-
months, or dual users 
1012 -- Complete self-reported cessation 
at 12-months: 16% (51/319) 
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Randomized controlled trial 
Caponnetto et al. 201342  
Caponnetto et al. conducted the first randomized controlled trial ECLAT to study the 
efficacy and safety of electronic cigarettes. This study was a prospective, 12-month 
double-blind, randomized, controlled trial to evaluate smoking reduction, smoking 
abstinence and adverse effects among smokers not intending to quit smoking. Study 
participants recruited for this study were regular smokers from Catania (Italy) smoking ≥ 
10 cigarettes per day, between 18 and 70 years old and in general good health. 
Participants were randomized into three groups on the basis of two different nicotine 
strengths of e-cigarettes: Group A (n = 100) received 12 weeks supply of 7.2 mg 
nictoine cartridge; Group B (n = 100)  received two 6-week supplies of nicotine 
cartridge: first 6-weeks for 7.2 mg nicotine cartrdige and for the next 6-weeks reciveing 
a supply of 5.4 mg nicotine cartridge; Group C (n = 100)  receiving 12 weeks supply of 
e-cig cartridges with no nicotine in it. The most popular electtronic cigarettes brand 
‘Categoria’ was utilized for this study. Study outcomes evaluated were smoking 
reduction (number of cigarettes smoked/day) and smoking abstinence (exhaled carbon 
monoxide (eCO) level; concentration of ≤ 7 ppm). 
During each study visit, significant differences were observed in all three study groups 
when compared to its baseline(P < 0.001). However, no significant differences were 
observed among three study groups. With the intention to treat analysis and excluding 
quitters, smoking reduction rates ( ≥ 50% decrease in the number of cigarettes 
smoked/day) from baseline for week-12 were 26%, 20% and 21% for groups A, B and C 
respectively, while for week-52 smoking reduction rates were 10%, 9% and 12% for 
 
 
34 
 
groups A, B and C respectively. Similary, smoking abstinence rates with an intention to 
treat analysis for week-12 were 11%, 17% and 4% for groups A, B and C respectively, 
while for week-52 abstinence rates were 13%, 9% and 4% for groups A, B and C 
respectively.  
Authors also examined outcomes releated to adverse events and product preferences. 
A significant reduction in the frequency of reported symptoms from the baseline were 
found at each clinic visit for all the three study groups. However, there were no 
significant differences among the sutdy groups for the adverse events at each time 
period. For the results related to the participants perception for e-cigs use over time, 
participants were highly willing to recommend these devices to friends or relatives for 
quitting smoking and found the overall product use to be satisfactory.  
Study authors concluded that based on the study results, e-cigs holds a promise to help 
smokers reduce the number of cigarettes smoked per day and can achieve abstinence 
from tobacco for long time. As participants in this study were the one with no intention to 
quit smoking, the overall smoking abstinence rate of 8.7% at 52-week along with the 
significant decrease in the frequency of adverse events from baseline was noteworthy. 
However, as the long term side effects associated with the e-cigs use were not a part of 
this study, the study results questions uncertainty over its long-term use and absitnence 
among regular smokers.  
Bullen et al. 201343  
Bullen et al. conducted pragmatic randomized-controlled superiority trial to investigate 
the efficacy of e-cigarettes over nicotine patches for its use in smoking cessation. The 
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study participants recruited were regular smokers from Auckland, New Zealand smoking 
≥ 10 cigarettes per day for the past year, 18 years and older and with the  intention to 
quit smoking. Participants were randomized into three study groups into 4:4:1 ratio 
using randomized block size nine design. Group A (n=289) received 16 mg nicotine e-
cigs, group B (n=295) received nicotine patches (21 mg patch, once daily) and group C 
(n=73) received placebo e-cigarettes (no nicotine) from week-1 before until week-12 
after quit day with low intensity behavioural support via voluntarily telephone 
counselling.  The e-cigarettes and cartridges utilized for this study were Elusion brand 
products provided by PGM international. Primary outcome evaluated was biochemically 
verified continuous smoking abstinence at 6 months (exhaled carbon monoxide (eCO) 
level; concentration of < 10 ppm). 
With an intent to treat analysis, out of the total 657 individuals who were randomized to 
the above three treatment groups, verified continuous smoking abstinence at 6 months 
after quit day was highest in group A (7.3%; 21 of 289), followed by group B (5.8%; 17 
of 295) and group C (4.1%; 3 of 73). Risk difference for nicotine e-cigs vs patches was 
1.51 (95% CI: -2.49  to 5.51) while for nicotine e-cigs vs placebo e-cigs was 3.16 (95% 
CI: -2.29  to 8.61). Quit rates were higher initially and then it decreased significantly in 
all study groups.  In group A, 57% of study participants reduced their daily cigarettes 
consumption by at least half at 6 months significantly while for group B it was 47%. 
There were higher number of adverse events reproted for group A (137 events) over 
group B (119 events) and group C (36 events). However, there were no significant 
differences in the adverse events reported between study groups and there were no 
evidence of association between adverse events and study intervention. Adherence to 
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the study treatments were higher for group A and group C over group B for 1st, 3rd and 
6th month. Study participants were highly willing to recommend e-cigs device to friends 
or family for quitting smoking as there was a sustained enthusiasm found to use these 
devices even at 6th month. 
Study authors concluded that e-cig devices with or without nicotine were modestly 
effective in achieving smoking abstinence over nicotine patches and possess relatively 
few adverse events associated with its use. However the study results cannot be 
concluded with certainty as sample size was insufficient to conclude superiority of 
nicotine e-cigs over pathces or to placebo e-cigs. Also, there were higher loss to follow-
up and withdrawal rates for nicotine patches than those assigned to e-cigs group. 
Further research is needed to establish more evidence for e-cigs long term benefits and 
harms for its use in smoking cessation at invidual and population levels.  
Adriaens et al. 201461  
In this randomized controlled clinical trial, authors analyzed the effectiveness of second 
generation e-cigs to evaluate acute cravings, smoking reduction and smoking 
abstinence among regular smokers over the period of eight months. Study participants 
who were unmotivated to quit were randomized into three groups; two experimental 
groups both receiving e-cigs and one control group who received nothing and were 
allowed to smoke continuously during the first 8 weeks of the study. Participants were 
recruited from the area around Leuven, Belgium between December 2012 and February 
2013. Participants were current smokers, smoking ≥ 10 factory made cigarettes for at 
least 3 past years, not motivated to quit but willing to try out less unhealthy alternative. 
Two types of e-cigs from second generation were evaluated (“Joyetech eGo-C” and the 
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“Kanger T2-CC”). 30 ml bottles of flavored tobacco with 18 mg/ml of nicotine were used 
as a volume and dose strength respectively. After attending the lab sessions, 
participants were followed up at 3- and 6-months to assess changes in smoking 
behavior and evaluate smoking cessation outcomes. Exhaled carbon monoxide (eCO) 
and saliva cotinine levels were also measured.  
Results indicates that at two months, among e-cig users group, 34% of them stopped 
smoking tobacco cigarettes, whereas none of them were able to stop smoking 
cigarettes in the control group (p < 0.01). At 5th month, total quit rate among e-cig users 
were 37% whereas the quitting rate among control group three months after initiating e-
cig use was 38%. Smoking abstinence rate at 8 month among e-cig users and control 
group were 19% and 25% respectively. Overall there was 60% reduction in the amount 
of cigarettes smoked/day at the end of study period when compared to start of the 
study. 50% self-reported sustained abstinence at 8th month among e-cig users were 
observed in almost half of the participants (44%).  
Authors concluded that among e-cig naïve tobacco smokers, second-generation e-cig 
devices were highly effective in reducing the quantity of cigarettes smoked per day and 
were helpful in reducing craving and withdrawal associated with tobacco smoke.  
Prospective cohort studies 
Polosa et al. 2011 (with intervention)62  
Polosa et al. conducted a prospective 6-month pilot proof-of-concept study to evaluate 
the efficacy of electronic cigarettes in smoking reduction and smoking abstinence and to 
monitor possible modifications in smoking habits among regular smokers not willing to 
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quit smoking. Study participants were healthy smokers, smoking ≥ 15 factory-made 
cigarettes/day for at least past 10 years, between 18 and 60 years of age group, 
unwilling to quit smoking and residing in Catania, Italy. Eligible participants were invited 
to use popular e-cig brand ‘Categoria’ and were followed prospectively for 6 months (at 
baseline, week-4, week-8, week-12 and week-24). Primary efficacy measure was 
sustained 50% reduction in number of cigarettes smoked/day for 30 days period prior to 
week-24 study visit from baseline (reducers). Secondary efficacy measure was 
sustained 80% reduction in number of cigarettes smoked/day for 30 days period prior to 
week-24 study visit from baseline (heavy reducers). Both these outcomes were self-
reported and were also confirmed during the study visit by measuring eCO level 
(concentration of ≤ 10 ppm) in participants breaths at the time of the interview. 
Additional secondary efficacy measure was sustained self-reported and eCO confirmed 
(concentration of ≤ 10 ppm) smoking abstinence at week-24 for 30 days period prior to 
week-24 study visit. 
A total of 40 participants were included and 67% (n = 27) of them completed this study. 
Sustained 50% reduction in the number of cigarettes smoked/day at week-24 was 
observed in 32.5% of the participants (13/40) with the median of 25 cigarettes 
smoked/day at baseline to 6 cigarettes smoked/day at week-24 (p < 0.001). Sustained 
80% reduction in the number of cigarettes smoked/day at week-24 was observed in 
12.5% of the participants (5/40) with the median of 30 cigarettes smoked/day at 
baseline to 3 cigarettes smoked/day at week-24 (p = 0.043). At week-24, sustained 
smoking abstinence was observed in 22.5% (9/40) participants where 2/3 of those 9 
were still using e-cigs at the end of the study. Overall at week-24, 55% (22/40) 
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participants achieved both sustained 50% reduction and smoking abstinence with 88% 
reduction in the number of cigarettes smoked/day. Adverse events that were frequently 
reported were mouth (20.6%) and throat irritation (32.4%), and dry cough (32.4%), 
however these adverse events reduced substantially at the end of study period. Number 
of cartridges used/day were not more than three throught the study period. Product 
opinion and acceptance was found to be good among study participants.  
Authors concluded that e-cigs use, although currently not regulated as a pharmaceutical 
products, can help smokers substantially in reducing the amount of cigarettes 
smoked/day or can help in achieving smoking abstinence. Specifically with the currently 
available pharmacotherpaies that are approved for smoking cessation, adding this new 
device as an alternate to the available smoking cessation options can help bring more 
smokers into treatment and can increase the numbers of smokers who are motivated to 
quit tobacco. Susbstituting e-cigs over tobacco can surely help in saving lives. This is 
the first e-cigs study that evaluated product efficacy and confirmed that these devices 
can help in reducing the amount of tobacco consumed per day among smokers who are 
unwilling to quit. However, the study findings pose some challenges as well. Due to the 
lack of control group in this study and with high loss to follow up (32.5%), observed 
positive effects can be simply due to chance and not the true effects. Also, due to its 
unusual study design, study results cannot be compared with any other smoking 
cessation products. 
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Caponnetto et al. 2013 (with intervention)63  
Capponetto et al. conducted a prospective 12-month pilot study to evaluate the efficacy 
of electronic cigarettes in smoking reduction and smoking abstinence among regular 
smokers with schizophrenia. Study participants were chronic schizophrenic patients 
(confirmed using ICD-10 codes and DSM-IV-TR criteria for schizophrenia), regular 
smokers smoking ≥ 10 cigarettes/day, not intending to quit and were recruited from 
Catania, Italy. Eligible participants were invited to use popular e-cig brand ‘Categoria’ 
and were followed at baseline, week-4, week-8, week-12, week-24 and week-52.  
Primary efficacy measure was sustained 50% reduction in number of cigarettes 
smoked/day for 30 days period prior to week-52 study visit from baseline. Secondary 
efficacy measure was self-reported smoking abstinence for 30 days period prior to 
week-52 study visit and was objectively confirmed measuring eCO level (concentration 
of ≤ 10 ppm) in breaths of study participants during their interview. Additionally, positive 
and negative symptoms of schizophrenia were measured during each clinic visit. The 
Scale for Assessment of Negative Symptoms (SANS) and the Scale for Assessment of 
Positive Symptoms (SAPS) were used to assess the positive and negative symptoms of 
schizophrenia.  
A total of 14 participants were included and completed this study. Sustained 50% 
reduction in number of cigarettes smoked/day at week-52 was observed in half of the 
participants (7/14) with the median of 30 cigarettes smoked/day at baseline to 15 
cigarettes smoked/day at week-52 (p = 0.018). At week-52, sustained smoking 
abstinence was observed in 14.3% (2/14) participants. Overall at week-52, 64.3% (9/14) 
participants achieved both sustained 50% reduction and smoking abstinence. Adverse 
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events reported were nausea (14.4%), throat irritation (14.4%), headache (14.4%) and 
dry cough (28.6%). The number of cartridges used/ day were not more than two 
throught the study period. Patients using e-cigs did not have any increase in both 
positive and negative symptoms of schizophrenia after smoking reduction or cessation.  
Authors concluded that e-cigs use, although currently not regulated as a pharmaceutical 
products, can help patients substantially in reducing the amount of cigarettes consumed 
per day or can help in achieving smoking abstinence and reduce the overall burden of 
smoking-related morbidity and mortality  in schizophrenic patients who smokes 
regularly. According to study participants, these devices had very few side effects and 
had no apparent increase in the withdrawal symptoms. However, these study findings 
cannot be easily translated and cannot be made generalizable due to very small sample 
size these study had. Study results are questionable for interpretation as positive effects 
due to e-cigs could have been simply due to chance and not a true product effect.  Also, 
these results cannot be compared with any other smoking cessation products because 
of the type of patient population that was being analysed.  
Ely J 2013 (with intervention)64  
The studys main objective was to offer a new smoking cessation alternative; e-
cigarettes along with other available options for quitting smoking in order to increase 
overall smoking cessation rates among current smokers residing in Moffat county and 
multiple surrounding areas of northwestern colorado. The secondary objective was to 
offer e-cigarettes as an alternative to tobacco smoke among those individuals who were 
not motivated to quit but were willing to switch to this new alternative which was 
hypothesized to be safe and cheaper over other alternatives. This program was 
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conducted at the Kinder Family Clinic for 6 months on a trial basis. Study intervention 
goal was to implement the structured, systematic smoking cessation program based on 
the ‘5 As’ and the transtheoretical model to treat tobacco use and dependence. 
Participants were informed of the variety of options at the beginning of the study and 
were provided with printed information on ‘smoketips’ and ‘blu cig’ e-cig brands, costs, 
nicotine dosage options and availability. Participants were provided a questionnaire and 
were followed up using telephone at 2-weeks, 1 month, 3 months and 6 months after 
the use of intervention.  
A total of 44 participants were recruited in this study where all of them used e-cigs, 16 
used bupropion, and 2 used Varenicline. Number of participants who quit smoking were 
32% (14/44) and 16% (7/44) of them switched to e-cigarettes. Of those who completely 
quit smoking (n = 14), 10 used solely e-cigs, 2 of them used bupropion and the rest 
used Varenicline. Of the 7 who switched to e-cigarettes, 3 of them used solely e-cigs 
and the rest used both, e-cigs and bupropion. A total of 23 remaing participants were 
unable to quit smoking, 30% (13/23) were able to reduce their daily smoking to half of 
their initial smoked level along with intiating the use of e-cigarettes. 6-month smokming 
cessatiion rate was 44% (21/44). Smoking cessation rate or switching rates to e-
cigarettes were both double in comparison to the national and state averages of 21-
24%, indicating intervention success and significant harm reduction for patients and 
families. Overall, smoking abstinence was not clearly defined nor was verified 
biochemically and hence possess high risk for other biases.   
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Polosa et al. 2014 (with intervention)65  
Polosa et al conducted a 24-month prospective observational study to evaluate the 
long-term effectiveness and tolerability of e-cigarettes in the real world settings. Study 
participants included were healthy current smokers, smoking ≥ 15 factory-made 
cigarettes per day for at least past 10 years, were not motivated to quit smoking and 
were recruited from the local hospital staff in Catania, Italy. Eligible participants were 
invited to use popular e-cig brand ‘Categoria’ for a period of 6 months and were 
followed up prospectively for 24 months (at baseline, week-4, week-8, week-12, week-
24, 18-months and 12-months). Efficacy measures evaluated were (1) 50% reduction in 
number of cigarettes smoked/day from baseline (reducers) at each study visit and was 
objectively confirmed by measuring eCO level (concentration of ≤ 10 ppm) in breaths of 
study participants during their interview. (2) 80% reduction in number of cigarettes 
smoked/day from baseline (heavy reducers) at each study visit and was objectively 
confirmed by measuring eCO level (concentration of ≤ 10 ppm) in breaths of study 
participants during their interview. (3) Sustained self-reported and eCO confirmed 
(concentration of ≤ 10 ppm) smoking abstinence at each study visit. 
Out of 40 subjects, almost 50% (n =23) of them completed this study. 50% sustained 
reduction in the number of cigarettes smoked/day at 6-, 18- and 24-months were 
observed in 10/40, 11/40 and 11/40 participants respectively with significant reduction in 
the median number of cigarettes smoked/day at 24-months (24 cigarettes smoked/day 
at baseline to 4 cigarettes smoked/day at 24 months). 80% sustained reduction in the 
number of cigarettes smoked/day at 6-, 18- and 24-months were observed in 4/40, 3/40 
and 6/40 participants respectively with reduction in the median number of cigarettes 
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smoked/day at 24-months (27.5 cigarettes smoked/day at baseline to 4 cigarettes 
smoked/day at 24-months). Smoking abstinence at 24-months was observed in 12.5% 
(5/40) participants while 40% (16/40) participants achieved both, 50% reduction and 
smoking abstinence). At the end of the study, 5 participants stopped using e-cigs, 3 
started using tobacco again and 4 upgraded to more advanced e-cig prodcuts. Adverse 
events reported were mouth and throat irritation, and dry cough. There were hardly any 
withdrawal symptoms that were reported for this study.  
Authors concluded that e-cigs can extensively help in reducing the amount of cigarettes 
smoked/day and can help in achieving smoking abstinence among smokers who are 
unwilling to quit smoking. This is the first study to examine the efficacy of e-cigs in 
smoking reduction and smoking abstinence for a long term period and in the naturalistic 
settings. Study results strongly supported e-cigs use and are more effective than 
approved pharmacotherapies for smoking cessation in more realistic settings. However, 
as there was a lack of control group in this study design along with higher loss to follow 
up, it presents challenges for applicability of study results to other settings.  
Polosa et al. 2014 (with intervention)66  
Polosa et al conducted a proof-of-concept prospective study to evaluate possible 
modifications in the daily cigarettes smoked among current smokers who switched to 
second-generation e-cigarettes with the focus on smoking reduction and abstinence. 
Study participants were healthy smokers, between 18 and 60 years old, smoking ≥15 
factory made cigarettes per day for at least 10 years, not motivated to quit and residing 
in Catania, Italy.  Qualified participants were invited to use a second-generation e-
cigarettes device: EGO/CE4 model filled with tobacco aroma e-liquid containing 9mg/ml 
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of nicotine. Participants were followed prospectively for 6-months at baseline, week-4, 
week-8, week-12, and week-24. Efficacy measures evaluated were (1) Self-reported 
sustained 50% reduction in number of cigarettes smoked/day compared to baseline for 
30 day period prior to week-24 (reducers). (2) Self-reported sustained 80% reduction in 
number of cigarettes smoked/day (heavy reducers)  and sustained abstinence (quitters) 
from baseline at week-24.  The eCO levels were also measured to confirm smoking 
reduction and abstinence (concentration of ≤ 10 ppm) during their interview. Smokers 
who werent able to qualify for either reducers, heavy reducers or quitters were 
categorized as failures. 
A total of 50 smokers participated in this study, with 38 of them being able to complete 
this study. 50% and 80% sustained reduction in the number of cigarettes smoked per 
day at week-24 was observed in 30% (15/50) and 14% (7/50) participants with 
significant reduction in the median number of cigarettes from 25 cigarettes smoked/day 
at baseline to 6 cigarettes smoked/day and 3 cigarettes smoked/day at week-24 
respectively. Smoking abstinence at week-24 was observed in 36% (18/50) participants, 
with 83.3% (15/18) of them still using the e-cig device. Collective 50% reduction and 
smoking abstinence was observed in 66% (33/50) participants. Adverse events reported 
were throat and mouth irritation (35.6%), dry throat and mouth (28.9%), headache 
(26.7%) and dry cough (22.2%). However, frequency of these reported events 
decreased substantially near the study completion. Overall patient’s acceptance and 
preferences in handling these second-generation devices were good.  
Smoking abstinence and reduction rates obtained in this study were not only higher in 
comparison to the reduction and abstinence rates for standard smoking cessation 
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options but were also higher in comparison to the smoking cessation studies using first 
generation devices. This may be due to high level of product satisfaction and reliability 
associated with the use of second generation devices. Study authors concluded that the 
use of second generation e-cigarettes in smoking cessation can help smokers in 
reducing the quantity of tobacco smoked per day along with increasing the likelihood of 
remaining abstinent for a long period of time. However, results cannot be made 
generalizable due to presence of study challenges such as lack of control group along 
with 32.5% of loss-to-follow up. Further study is needed that can compare first and 
second generation devices for its efficacy related to smoking reduction and abstinence. 
Pacifici et al. 2015 (with intervention)67  
Pacifici et al conducted 8-month pilot study among adult smokers to evaluate whether 
medically assisted e-cigarette uers were able to use nicotine successfully or not. In this 
pre-post uncontrolled pilot study, participants were adult smokers, not motivated to quit 
smoking, have never tried quitting tobacco use, and/or have never tried any smoking 
cessation treatments. Participants were recruited by word of mouth and it was 
conducted at the anti-smoking Centre at San Giovanni Bosco Hospital (Torino, Italy). 
Since 2000, this centre supplies customized smoking cessation treatments to an 
average of 300 smokers/year. Participants were given a couple of commercially 
available e-cigs AVATAR device, chargers and nicotine liquid (that matches individuals 
daily nicotine intake). Further, they were given face-to-face medical training for how to 
correctly use e-cig devices to absorb nicotine vapor. Participants were followed up at 
first, fourth and eigth month for analysis of eCO level, blood cotinine and 
hydroxycotinine levels along with the information on number of cigarettes smoked/day. 
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Total of 34 participants were recruited for this study and were aged 18-63 years old. At 
the end of first month, participants were grouped as only e-cig users (73%), dual users 
(17.6%) and only cigarette users (8.8%). Over time, significant reductions in the eCO 
level were found for both e-cig users only and dual users group. Overall smoking 
abstience at the end of 8-month was about 53%. Also, number of cigarettes 
smoked/day decreased significantly at 8-month for all three groups compared to the 
start of the study. However, no significant differences were found for the cotinine and 
hydroxy-cotinine levels for any any of the groups.  
Authors concluded that providing medical training to smokers on how to use e-cigs 
device can help in successful nicotine intake, can reduce the overall craving for 
cigarettes and can avoid side-effects associated with nicotine overdosage. However 
due to lack of control group and less sample size, study results cannot be made 
generalizable. Further results from clinical trial study evaluating medically assisted use 
of e-cigs with more number of participants are needed.  
Polosa et al. 2015 (with intervention)68  
In this study, authors evaluated the changes in the quanity of cigarettes smoked/day 
among smokers who made their first e-cigs purchase at vape shops. This was a 
prospective pilot study conducted for 12-months with study participants being adult (≥ 
18 years) and making their first e-cig purchase at the participating local vape shops in 
the city of Cantania (Sicily). Participants were motivated to use e-cig products with the 
purpose of achieving reduction in the amount of cigarettes smoked/day. Participants 
were asked specific set of questions by the professional retail staff and were followed 
prospectively at 6-months and 12-months. Participants were instructed on how to 
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charge, fill, activate and use e-cig products. Study outcomes evaluated were (1) Self-
reported sustained 50% reduction in number of cigarettes smoked/day compared to 
baseline for 30 day period prior to a follow-up visit (reducers). (2) Self-reported 
sustained 80% reduction in number of cigarettes smoked/day (heavy reducers)  and 
sustained abstinence (quitters) compared to baseline for 30 day period prior to a follow-
up visit. Smokers who werent able to qualify for either reducers, heavy reducers or 
quitters and those who were lost to follow-up were categorized as failures. Changes in 
product purchases were also evaluated. 
Out of 71 participants who made their first e-cig purchase at local vape shops, 69% of 
them attended their final follow-up visit. With an intent to treat analysis, at the end of 
study (12-month), 25.4% were reducers, 40.8% were quitters and 33.8% were failures. 
Analyzing the whole cohort (n=71), the quantity of cigarettes smoked/day decreased 
from 24.9 cigarettes smoked/day (at baseline) to 4 cigarettes smoked/day and 2.6 
cigarettes smoked/day at 6- and 12-months respectively. Overall, aggregated smoking 
abstinence and smoking reduction at 12 months was observed in 66.2% (47/71) 
participants, with the mean number of cigarettes smoked/day being 24.7/day at baseline 
decreasing to 2.2 cigarettes smoked/day at the end of the study (89.1% reduction). 
Smoking abstinence rates at 6- and 12-months were 42% (30/71) and 41% (29/71) 
respectively. The combined usage (smoking and e-cig use) at 12 months was 66.2% 
indicating higher product satisfaction.  
Authors concluded that smokers making their first e-cig purchase from local vape shops 
and if provided professional advice and support can help in reducing the quanity of 
cigarettes smoked/day along with the increase in rates of achieving smoking 
 
 
49 
 
abstinance. However, limitations to this study were that both smoking reduction and 
abstinence were self-reported and were not biochemically verified. Additionally, due to 
less sample size, self-selection of participants and absence of controlled group, results 
cannot be generalized and cant be interpreted for its true effect.  
Etter et al. 2014 (without intervention)44  
Etter et al. conducted a longitudinal internet survey from 2011 to 2013 to evaluate 
behaviour change among e-cig users over a period of 12 months. Survey participants 
were registered online through smoking cessation website Stop-Tabac.ch 
(http://www.stop-tabac.ch/fr/) and were provided a questionnaire in english and french 
at baseline, 1-month and a year after to collect information on e-cig use, current 
smoking status, use of tobacco in previous 7 days, number of cigarettes consumed/day, 
puffs/day (1-year) and quitting date in former smokers. Participants with age over 18 
were only included in this study. Stop-Tabac.ch website ranks among the top five global 
sites for smoking cessation. It offers an online free help to smokers who wants to quit 
smoking, wants to prevent relapse and needed motivation to quit smoking. It provides 
information about smoking, its consequences and treatments and facilitates an 
opportunity to exchange dialogues between smokers and ex-smokers. 
Out of 1329 participants who answered survey at the baseline, 773 (58%) of them 
provided their email address. Out of those who provided their email address, 62% and 
47% of them participated in the survey at 1-month and 1-year respectively. 
Respondents were from the US (34%), France (24%), UK (8%), Switzerland (6%) and 
other countries (28%).   Majority of the participants were former smokers (72%), 76% of 
them were using e-cigs daily much like nicotine medications to assist quitting and were 
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abstinent from smoking for a median of 10 weeks. Among former smokers who were 
vaping daily at the baseline, 6% relapsed to smoking at both 1-month and 1-year. 
Among dual users (daily smokers and e-cig users), 22% and 46% stopped smoking 
after 1-month and 1-year respectively. Cigarette consumption among dual users 
decreased significantly from 11.3 cigarettes smoked/day at baseline to 6.0 cigarettes 
smoked/day at 1-month. However, it didn’t change significantly from baseline till 1-year 
of follow-up.  
As the study participants were from different countries with the survey response coming 
from the users who were in the real world settings, this study provided most detailed 
information on the natural behavior change for e-cigs use over 12 month period. 
Authors concluded that e-cigs act as an alternative to smoking, can help current 
smokers in quitting smoking and can help former smokers in avoiding relapse. The 
results agreed to the formerly conducted similar longitudinal and clinical trials for 
vapers. However, study results possess major limitations such as self-reported and self-
selection bias. Further research is needed that can evaluate health consequences of e-
cigarettes use in long term.  
Grana et al. 2014 (without intervention)69  
Grana et al conducted a longitudinal online survey among current smokers to evaluate 
whether e-cigarettes were helpful in quitting smoking or in reducing the quantity of 
cigarettes consumed per day. Participants recruited were from the Knowledge 
Networks; probability based online survey. Current smokers who completed baseline 
survey (November 2011) and follow-up (November 2012) online surveys were the one 
included in this study. E-cig use, number of cigarettes consumed/day, time to first 
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cigarette, and intention to quit were measured at baseline and follow-up. Descriptive 
and regression analysis were conducted on these study variables. 
Out of the total 1549 participants who were on the 2011 and 2012 survey panel, 1189 
were current smokers and 81.3% completed the follow-up survey. Greater amount of e-
cig users were among women, younger adults and those with less education. Baseline 
e-cig use among current smokers was not associated with greater intention to quit 
smoking (p = 0.09). In addition, the use of e-cig at baseline did not predict quitting 
smoking 1-year later (OR: 0.76; 95% CI: 0.35, 1.46). However, study model that 
included intent, dependence and consumption study variables found that intent (OR: 
5.59; 95% CI: 2.41, 12.98) and consumption (OR: 0.97; 95% CI: 0.94, 0.99) significantly 
predicted quit status. Among those who were smoking both at the baseline and follow-
up, e-cig use was not associated with the change in cigarette consumption (p =0.25).  
Authors concluded that e-cigarettes may not help smokers in quitting smoking or 
reducing the amount of cigarettes smoked and hence proposed that regulations should 
prohibit any advertisement of e-cigs that claims it to be effective in smoking cessation 
unless scientific evidences supporting its use in smoking cessation becomes available. 
The study results were in agreement to the other longitudinal population-level study. 
These study pose several study limitations such as lack of detailed information on 
frequency, duration, use patterns and motivation for e-cig use, self-reported bias and 
was limited in statistical power to conclude for the significant relationship between e-cig 
use and quitting. 
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Borderud SP et al. 2014 (without intervention)70  
In this study, authors analyzed clinical characteristics and cessation outcomes among 
cancer patients who were referred to the Tobacco Treatment Program (TTP) at 
Memorial Sloan-Kettering Cancer Center, New York from January 2012 till December 
2013.  Participants in this study were current smokers, diagnosed with cancer and 
referred to the TTP. E-cig users were those who responded yes to using these devices 
within 30 days prior to enrollment. Patient information was collected at baseline and 
were followed up at 6th and 12th months through telephone to collect information on 
smoking cessation.  
Out of total 4054 patients who were referred to this program, 1074 of them were 
recruited. During baseline, around 25% of the patients (n=285) were using e-cigs; 92% 
of them reported smoking tobacco as well. The number of e-cig users increased 3 times 
from 2012 to 2013 (10.6% vs. 38.5%). There were no significant differences for 
demographic characteristics between e-cig users and nonusers. Among those using e-
cigs, proportion of use were higher among those with thoracic or head and neck 
surgery. Also, e-cig users were more nicotine dependent and had more prior quit 
attempts in comparison to nonusers. With an intent to treat analysis, e-cig users were 
highly likely to be smoking tobacco at the follow-up in comparison to nonusers (OR: 2.0; 
95% CI: 1.2 to 3.3)  
Authors concluded that in past two years, awareness and use of e-cigs has not just 
increased in the general population, but it has also shown rise in disease population 
such as those having cancer. However, there is still an uncertainty regarding the use of 
this device officially for smoking cessation in cancer patients. Further studies are 
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needed that can evaluate the effectiveness of this devices as a cessation treatment in 
patients with cancer. 
Prochaska et al. 2014 (without intervention)71  
In this secondary analysis from a three group randomized clinical trial data, authors 
evaluated whether e-cig use was associated with any changes in smoking behavior 
among patients with mental illness. Participants recruited for this study were adult 
smokers smoking at least five cigarettes daily, not willing to quit tobacco and were 
recruited during their acute psychiatric hospitalization. Recruitment was done in San 
Francisco Bay area during 2009 and 2013, with the study intervention being tailored and 
computer assisted for readiness to quit, a stage-tailored manual, brief stage-tailored on-
unit counseling session with study staff, and participants were provided combination 
nicotine replacement therapies available following hospitalization. NRT was offered for 3 
months in the brief treatment arm and for 6-months in the extended treatment arm. The 
latter group also received 10 sessions of cognitive behavioral cessation counseling.  
Participants were followed up at 3, 6, 12 and 18 months.  
73% (n = 956) of adult smokers were enrolled at the baseline.  Average number of 
cigarettes smoked/day at baseline was 17 (SD =10) and 24% of them intended to quit 
smoking in the next month. E-cig use increased from 0% at the year of enrollment to 
25% in 2013. The likelihood of using e-cig increased with each additional year of 
recruitment, for those between 18 and 26 years, for those in the preparation vs pre-
contemplation stage of change. At 18 month, e-cig use was not associated with either 
change in smoking status or reduction in the quantity of cigarettes smoked per day.  
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Authors concluded that among current smokers with mental illness, e-cig use has 
increased over time. However, there was no correlation found between those using e-
cigs and smoking status or quantity of cigarettes consumed per day and challenges 
interpretability of study results due to the presence of self-selection and reporting bias. 
Choi et al. 2014 (without intervention)72  
Authors in this study evaluated a longitudinal data to analyze the relationship between 
the beliefs and perceptions to its subsequent experimentation with e-cigs. Minnesota 
Adolescent Community Cohort (MACC) data was utilized. Participants were young 
adults (N = 1379) from Minnesota who never used e-cigs at baseline (Oct 2010 until 
March 2011) and were able to follow up at 1-year (Oct 2-11 until Mar 2012). At baseline, 
participants were asked about their beliefs for e-cigs with respect to its harmfulness, 
addictiveness and as a potential for quitting smoking. At the end of study, information 
regarding their ever usage of e-cigs were collected. Association between beliefs and 
subsequent experimentation with e-cigs were evaluated with the help of logistic 
regression models.   
Results found that during the end of study, 7.4% (n = 102) participants reported using e-
cigs ever, 21.6% of whom were baseline current smokers. Participants with the positive 
beliefs that e-cigs can help people in quitting smoking and are less harmful than 
conventional cigarettes were the ones to be more likely to be experimenting e-cigs at 
follow-up (p <0.05). Authors also found that 11% of smokers who had ever used e-cigs 
at baseline had quit smoking at 1-year follow-up compared with 17% of smokers who 
had never used e-cigs.  
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Results from this study cannot be made generalizable due to the presence of 
predominantly white sample and participants coming from one particular region. Authors 
concluded that prior beliefs about e-cigs are highly associated with the subsequent 
experimentation to these products. However, due to existing uncertainty with e-cigs 
long-term harmfulness and addictiveness, providing young adults with these may 
discourage them from trying these products.  
Brown et al. 2014 (without intervention)45  
In this large cross sectional survey, authors examined the effectiveness of e-cigarettes 
over standard therapies available for smoking cessation in the real world setting. 
Participants were adult population (n = 5863) representative of the English population 
residing in England, recruited between July 2009 until February 2014, who smoked or 
used any tobacco products at the time of recruitment, made at least one quit attempt 
with either e-cigs only (n = 464), or bought OTC NRT only (n = 1922) or no aid (n = 
3477) in the past one year before enrollment. Primary outcome was adjusted self-
reported smoking abstinence until the time of survey.  
Results indicated that those who used e-cigs for quitting were more likely to remain 
abstinent from smoking (OR: 2.23; 95% CI: 1.7 to 2.93) in comparison to those who 
used NRT purchased OTC. After adjusting for key potential confounders, the odds of 
not smoking were still higher among e-cig users (OR: 1.63; 95% CI: 1.17 to 2.27) in 
comparison to those using NRT or using no aid. 
Authors concluded that those using e-cigs as a smoking cessation tool were more likely 
to have continued smoking abstinence. However due to the nature of study design, it 
 
 
56 
 
questions the observed true effectiveness and temporality. Additionally, smoking 
abstinence was not biochemically verified and there was a heavy reliance on recall 
data. 
Brose LS et al. 2015 (without intervention)73  
In this study, authors evaluated the association between e-cig use and smoking 
cessation attempts, cessation and substantial reduction among smokers while 
considering for frequency of use and including important confounders. A web-based 
longitudinal survey was conducted in Great Britain between 2012 and 2013. Study 
participants were invited online through a panel managed by Ispos MORI. Ispos MORI 
is one of the biggest market research organization in the UK. Participants were emailed 
questionnaires at baseline and at 1-year. Outcomes evaluated were cessation attempts, 
cesation and ≥ 50% self-reported substantial reduction in number of cigarettes 
smoked/day. Further, adjusted logistic regression models were built to analyze the 
association of cessation attempt in last year and smoking status on baseline e-cig use. 
Additionally, the association between substantial reduction and follow-up e-cig use were 
also evaluated while adjusting for all the required variables. 
Total 5000 respondents completed this survey, 4064 of them were current smokers with 
age over 18. Loss to follow-up was 43% (1759/4064) indicating that 46% of them 
attempted to quit smoking in 1-year. Of those using e-cigs at baseline, majority of them 
were first generation e-cig users (‘Cigalike’). Daily e-cig use at baseline was associated 
with increased odds of cessation attempts but not with cessation in comparison to non-
use. (OR: 2.11; 95% CI: 1.24-3.58). Daily e-cig use at follow-up was associated with 
increased odds of substantial reduction (OR: 2.49; 95% CI: 1.14-5.45).  However, non-
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daily use was found to be neither associated with cessation attempts nor cessation. 
Smoking abstinent rate at 12-months among the participants was found to be very low 
(8%). 
Authors concluded that regular use of e-cigs among smokers can help in increasing the 
rates of quit attempts and reducing smoking. However, they might not be that helpful in 
smoking cessation. However, nature of this study design warrats the applicability of 
study results to make it more generalizable. This study poses challenges such as 
selection bias, attrition bias and reporting bias.  
Al-Delaimy et al. 2015 (without intervention)74  
In this prospective cohort study, authors evaluated whether ever use of e-cigs among 
smokers affected smoking abstinence and smoking habits among general population in 
comparison to those who never used e-cigs. California Smokers Cohort (CSC) data was 
analyzed at two time points; at baseline and at 1-year among current and former 
smokers residing in California. Baseline survey consisted of telephone interview of 4350 
residents from California who were between 18 and 59 years old and had smoked at 
least 100 cigarettes during their lifetime. At baseline, 83.6% were daily smokers and 
236 participants reported using E-cigs at that time point. During the follow-up at 1-year, 
1745 participants responded over telephone of whom 1000 were smokers at baseline. 
Analysis involved only smokers who reported using e-cig at both baseline and follow-up. 
Self-reported abstinence at 1-year, quit attempts and smoking reduction were assessed 
at 1-year. Logistic regression model was developed to assess the association of history 
of use of e-cigs at baseline to predict quitting behavior at 1-year follow-up after adjusting 
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for confounders at baseline. Analysis involved only smokers who reported using e-cig at 
both baseline and follow-up.  
Authors found that females, Hispanic whites and daily smokers were the one who were 
significantly more likely to report using e-cigs ever both at baseline and follow-up. In 
contrast to other studies, these study found that in comparison to smokers who never 
used e-cigs, smokers who used e-cigs ever were significantly less likely to reduce their 
daily amount of cigarettes smoked (OR: 0.51; 95% CI: 0.30 to 0.87), and were also less 
likely to quit smoking for 30 days or more at 1-year (OR: 0.41; 95% CI: 0.18 to 0.93). 
Smoking abstinence at 12-months was 5% (12/236) among ever e-cig users while 
among never e-cig users, it was 10.5%. However, those who used e-cigs ever were 
more likely to have a quit attempt (OR: 1.15; 95% CI: 0.67 to 1.97).  
Authors concluded that those who had ever used e-cigs pose a higher risk of not being 
able to quit smoking; a study finding which contrasts majority of study findings from 
randomized clinical trials and experimental studies. However, this study possesses 
major challenges such as risk of recall bias, self-selection bias and attrition bias. Also, 
intervention was not clearly mentioned and authors didn’t collect information on the type 
of e-cigs used as this could affect study results. Additionally, motivation status of 
participants were also not clear.   
Manzoli 2015 et al. (without intervention)75  
In this prospective cohort study, authors evaluated the safety and efficacy of e-
cigarettes as a tool for smoking cessation by comparing only e-cig users, only tobacco 
smokers and smokers of both. This study was initiated in 2013 in a community settings 
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in Abruzzo, Italy and is expected to follow-up until 5 years to evaluate long-term efficacy 
of e-cigs, with the final study results being expected in 2019. However, authors have 
published main results from the 1-year follow-up. Participants were recruited through 
direct contact with physicians and e-cig shops by posting online advertisement and 
social networks. Participants between 30 and 75 years of age group were included and 
were grouped either as e-smokers (had smoked any brands of e-cigs and inhaling ≥50 
puffs weekly for the past 6 months), or tobacco smokers (smoked ≥1 tobacco cigarette 
per day for the past 6 months) or dual smokers (smoked both e-cigs and tobacco within 
the same week for past 6-months).  Participants were surveyed face-to-face at baseline 
and through telephone at 12-months using structured survey questionnaire. Outcomes 
evaluated were self-reported sustained (30 days) smoking abstinence at 12-months with 
CO validation for subsamples, proportion of quitters, quantity of tobacco cigarettes 
smoked, adverse events and self-reported health. Linear and logistic regression models 
were developed with region as a cluster unit. 
During 12-momths, follow-up data were available for 491 tobacco smokers, 236 e-cig 
smokers and 232 dual smokers, with response rate being 70.8%. All e-cig users were 
former tobacco smokers since more than 20 years on average. At follow-up, 61.9%, 
20.6% and 22.0% were abstinent from tobacco smoking among e-cig users, tobacco 
smokers and dual smokers respectively. Multivariate regression model results indicated 
that odds of continued tobacco smoking abstinence were higher among e-cig users 
(OR: 5.19; 95% CI: 3.35 to 8.02) in comparison to the tobacco users only. However, 
odds of remaining abstinent from smoking tobacco were not significant among dual 
users in comparison to tobacco users only, nor did it increased likelihood of reducing 
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tobacco consumption. Self-rated health among e-cig users were minimal but 
significantly higher in comparison to other groups. Adverse events reported among 
three groups were not significant.  
This is the first study that compares e-cig users with tobacco users and aims to collect 
long-term safety and efficacy data on e-cigarettes. With the study getting over in 2019, it 
will be interesting to see the real world effectiveness of these devices when used for 
long time and percentages of those being relapsed to smoking. Based on preliminary 
analysis of one-year data, authors concluded that there were no major safety concerns 
reported among e-cig users. Among dual users and tobacco smokers, there were no 
significant reduction in the quantity of cigarettes consumed and smoking abstinence. 
However, e-cig users were able to remain abstinent from smoking for long period along 
with no major safety issues being reported, holding them to be promising as an 
important tool to be used in smoking cessation.  This study is further planned to have a 
follow-up at 24-months, 36-months and 60-months.  
Summary of the literature 
Of all the included studies that have attempted to measure the effect of e-cigarettes in 
smoking cessation, most of them were online surveys or telephone based surveys, 
while the rest were conducted either at clinics, or at particular region. The majority of 
them included participants that were healthy adults (with age 18 and above), currently 
smoking tobacco and were not motivated to quit tobacco, while in the studies by 
Caponetto et al. and Borderud et al. it was specifically targeted among patients having 
schizophrenia and cancer respectively. Further, in many studies there was no specific 
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intervention that was being studied or applied, as the habits of using e-cigs were 
evaluated to analyze the smoking cessation outcomes. 
Currently e-cig devices are available in various brands and flavors.49 They are mostly 
categorized into four-generation devices with respect to different size and shape 
available. Also, they are available online for purchase with different levels of nicotine 
concentrations in cartridges (refilled and not-refilled). As a result, there is a considerable 
variability in nicotine vaporization between different types of e-cigarettes leading to 
different results for smoking cessation.32 A major challenge that remains with all the 
above included studies is that majority of them have considered first generation e-cigs 
device for its effectiveness in smoking cessation (using ‘cigalikes’). However, a study by 
Adriaens et al. conducted a randomized controlled trial to actually compare two second 
generation e-cig devices for its product effectiveness in cessation. Effectiveness of 
these devices in cessation using either third or fourth generation still remains 
questionable. Further, only 2 studies (Brown et al. and Bullen et al.) did compared the 
effectiveness of e-cigs with NRT’s. There were no head-to-head trial comparison 
studies available that compared e-cigs with other standard pharmacotherapies such as 
Varenicline or Bupropion. Such comparison studies are needed in the future to evaluate 
the product efficacy and to conclude for smoking abstinence.  Smoking reduction 
outcomes that were evaluated were reduction in number of cigarettes consumed per 
day and smoking cessation. ≥ 50% reduction in number of cigarettes smoked per day 
ranged from 25% to 57% at 6-months, 50% at 12-months, 28% at 24-months. ≥ 80% 
reduction in number of cigarettes smoked per day ranged from 1% to 14% at 6-months 
and was 15% at 24-months. Self-reported continuous smoking abstinence rate for all 
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the above included studies ranged from 7.3% to 44% at 6-months, 5% to 53% at 12-
months and 13% at 24-months. 
The majority of the studies found significant differences in the results related to smoking 
cessation outcomes compared with NRT’s and no cessation options and concluded that 
e-cigs can be used officially as a smoking cessation alternative and can help smokers 
substantially in reducing the amount of cigarettes consumed per day, can help in 
achieving smoking abstinence, and can reduce the overall burden of smoking-related 
morbidity and mortality. However, few of them didn’t find any significant difference and 
concluded them to be not helpful in quitting smoking. In fact they concluded that such 
devices can serve as a gateway to start smoking tobacco. Overall, from all the studies 
included, it is not possible to draw a reliable conclusion from these published study 
results for the effectiveness of e-cigarettes in smoking cessation due to methodological 
limitations such as self-selection bias, self-reported bias, poor sampling techniques or 
recruitment methods, inadequate blinding, wide confidence intervals or lack of statistical 
significance, and low internal validity. Also, scarcity of controlled studies regarding the 
effectiveness of e-cigs in broader population presents another challenge with regards to 
the generalizability of study results.   
2.2: Gaps in the literature 
Existing literature have evaluated efficacy and safety of e-cigs for smoking cessation. 
However, majority of them have evaluated smoking abstinence mainly in healthy adults, 
who were currently smoking and were not motivated to quit. None of them have 
evaluated the effectiveness of these devices among COPD patient population, as 
smoking cessation is the only evidence-based strategy that is identified to improve the 
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prognosis of COPD. Smoking cessation in COPD individuals has been shown to 
improve health status, decrease the respiratory symptoms of cough and sputum and 
has diminished the rate of annual decline in pulmonary function.76 It has also shown to 
reduce the risk of developing lung cancer, cardiovascular disease and other smoking-
related illness.21  Further, all studies have compared efficacy and safety of e-cigs either 
with placebo or with NRT’s. None of them have compared e-cigs with other standard 
available prescription pharmacotherapies such as Varenicline or Bupropion. Even 
though these prescription pharmacotherapies and NRT’s have shown to encourage 
cessation among current smokers with COPD, the relapse rate is very high when 
compared to smokers in general population.77 Due to more frequent relapses and 
ineffective smoking cessation among COPD patients, improved quit rates would be 
highly desirable among these specific group of patients, demanding the need for more 
efficient and novel approaches to quitting smoking.  Considering much increased 
awareness, popularity and use of e-cigs device for smoking cessation, it will be very 
essential to conduct a study that can compare these pharmacotherapies with e-cigs 
directly in order to evaluate the product efficacy for longer duration on the basis of 
established evidences. Another gap identified in the literature is that it remains unknown 
as to how introducing e-cigs as a smoking cessation therapy will impact the US 
healthcare budget, especially among COPD patient population. Further, there remains a 
need to estimate the prevalence and identify e-cig user characteristics among COPD 
patient population as these estimates can give a detail picture about the actual uptake 
and user characteristics of these devices among COPD patient population.  
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2.3: Specific Aims 
Aim 1: To estimate the prevalence and study sociodemographic predictors for e-
cig users among individuals with COPD in the United States (US) 
A. To estimate the prevalence for current e-cig users and ever e-cig users among 
individuals with COPD 
B. To identify the sociodemographic predictors for current e-cig users among individuals 
with COPD 
C. To examine the association between current e-cig users and sociodemographic 
predictors among individuals with COPD 
Aim 2: To examine the predictors and estimate the total healthcare cost among 
current smokers with COPD in the US 
A. To examine the sociodemographic and clinical characteristics among current 
smokers with COPD 
B. To estimate the unadjusted total, direct and indirect healthcare cost among current 
smokers with COPD 
C. To estimate the adjusted total, direct and indirect healthcare cost among current 
smokers with COPD 
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Aim 3: To estimate the economic impact of adopting e-cigarettes as a smoking 
cessation tool among current smokers with COPD in the US 
A: To estimate the 1-year and accumulated 5-year total healthcare cost savings 
associated with E-cigarettes (e-cigs) use in comparison to smoking cessation therapies 
among current smokers with COPD in the US 
B: To estimate the 1-year and accumulated 5-year total healthcare cost savings by 
gender associated with e-cigs use in comparison to smoking cessation therapies among 
current smokers with COPD in the US  
C: To estimate the 1-year and accumulated 5-year total healthcare cost savings by 
different age groups associated with e-cigs use in comparison to smoking cessation 
therapies among current smokers with COPD in the US  
2.4: Study significance:  
E-cig devices are unregulated by the US FDA and their use have dramatically 
increased. At the same time, many organizations are strongly advocating the use of 
these devices in quitting smoking. Hence, analyzing and understanding the economic 
impact of adopting e-cig devices amongst COPD diagnosed populations can help 
answer policy questions related to their use in smoking cessation. The results from this 
study can help policy makers, payers, consumers and clinicians make informed 
decisions about its use as a therapeutic device.  
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Chapter 3: Specific Aim 1 
Aim 1: To estimate the prevalence and study sociodemographic predictors for e-
cig users among individuals with COPD in the United States (US) 
A. To estimate the prevalence for current e-cig users and ever e-cig users among 
individuals with COPD 
B. To identify the sociodemographic predictors for current e-cig users among individuals 
with COPD 
C. To examine the association between current e-cig users and sociodemographic 
predictors among individuals with COPD 
3.1: Methods 
Design: Retrospective, cross-sectional design 
Data 
The National Health Interview Survey (NHIS) data was utilized for this study. The NHIS 
is an annual cross-sectional survey of the nationally representative, non-
institutionalized, US civilian population. The survey is conducted annually by the 
National Center for Health Statistics of the CDC. It uses a complex, stratified, 
multistage, probability design, where data collection comes from face-to-face interviews 
of participants with age 18 and above. This data monitors the health of the US 
population by collecting relevant information on the sociodemographic and economic 
characteristics of the sample participants. Further information on the NHIS methodology 
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is available online.78 This study was exempt from the Institutional Review Board (IRB) 
as this data is publicly available.   
Study population 
The 2014 sample adult file was utilized to measure the study objective, as this was the 
first time that the information regarding the usage for e-cigs were captured in the NHIS 
survey questionnaire. The sample file consisted of 36,697 survey respondents with age 
18 years or older with the response rate from the survey participants being 58.9%. For 
this study, participants with age 18 and above, and having diagnosed with COPD were 
included. Individuals with COPD were the ones who answered yes to the following 
survey question:  
 Have you EVER been told by a doctor or other health professional that you had 
chronic obstructive pulmonary disease, also called COPD? 
Study variables 
Key variable for this study was e-cigarettes use. Current e-cig users were defined as 
those having responded using e-cigarettes either every day or some days to the 
following survey question: 
 “Do you now use e-cigarettes every day, some days, or not at all?” 
 Ever e-cig users were defined as those having responded using e-cigarettes even one 
time in the past to the following survey question: 
  “Have you ever used an e-cigarette, even one time?” 
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Sociodemographic predictors that were included in this study were age (18-44 years, 
45-64 years, ≥ 65 years), gender (Men, Women), race (White, African American), 
marital status (Married, Widowed, Divorced/Separated, Never married), region 
(Northeast, Midwest, South, West), BMI (Normal, Overweight/Obese), smoking status 
(Current smokers, Former smokers), current working status (Working, Not working), 
place of employment (Private firm/Self-employed/self-employed, Federal/State/Local 
government employee), currently smoking tobacco products other than cigarettes every 
day or some days (Yes, No), currently using smokeless tobacco products every day or 
some days (Yes, No), have tried quitting smoking in the past one year more than once 
(Yes, No), and have tried quitting tobacco in the past one year more than once (Yes, 
No). Current smokers were defined as those who ever smoked 100 cigarettes and are 
currently smoking cigarettes either every day or some days. Former smokers were 
defined as those who ever smoked 100 cigarettes and are not smoking cigarettes 
currently. Further, smoked tobacco products other than cigarettes included cigars, 
pipers, hookahs or water pipes, very small cigars, bidis or cigarillos. Smokeless tobacco 
products included products that can be placed in the nose or mouth such as chewing 
tobacco, snuff, snus, dip, or dissolvable tobacco. 
Statistical analysis 
Prevalence estimates for current e-cig users and ever e-cig users among individuals 
with COPD were calculated using the survey sample weights in order to represent the 
estimates at the national level. Further, descriptive statistics (weighted frequency, %, 
std.error) were calculated to describe the sociodemographic predictors for current e-cig 
users among individuals with COPD. The Rao-Scott Chi square test was employed to 
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test the research hypothesis that no association existed between current e-cigs use and 
sociodemographic variable categories in the selected population, and that the variable 
analyzed would be statistically independent.  
Bivariate and multivariable analysis were performed using logistic regression (PROC 
LOGISTIC) to estimate the association between current e-cig users and 
sociodemographic predictors among individuals with COPD. The logistic regression 
model was intended to be parsimonious and hence, all the predictor variables for the 
model were selected based on literature and of practical significance. All 
sociodemographic variables that were used to study the descriptive characteristics were 
included in bivariate and multivariable analysis.  
There was a problem encountered while performing bivariate logistic regression 
analysis. Some of the sociodemographic variables such as currently smoking tobacco 
products other than cigarettes every day or some days (Yes, No), and currently using 
smokeless tobacco products every day or some days (Yes, No), had a large amount of 
missing values within each variable category. Due to the large number of missing 
values, there were empty clusters and empty stratum in the bivariate analysis and the 
variance estimation for such variables omitted those empty stratums, causing an output 
with incorrect regression coefficients and odds estimates. Hence, for the multivariable 
regression analysis, we decided to build three models; first by incorporating these 
problematic variables and doing cluster analysis, second by deleting these problematic 
variables and doing analysis without cluster, third by deleting these problematic 
variables and doing analysis with cluster. The reason to build and study these three 
models was to study the impact of these problematic variables and cluster analysis on 
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the model output for the association between current e-cigs use and sociodemographic 
predictors. Further, out of three models, model with the stable parameter output was 
interpreted for the study association. 
Prior to the building of these three multivariable models, a collinearity check among the 
predictor variables was performed. Pearson correlation tests were employed using 
PROC CORR procedure.  Results found collinearity between two sociodemographic 
predictors; have tried quitting smoking in the past one year more than once (Yes, No), 
and have tried quitting tobacco in the past one year more than once (Yes, No). Pearson 
correlation co-efficient for these two variables was 0.809 (P < 0.0001), indicating the 
presence of collinearity between these two variables. Hence, based on variable 
significance, the variable that measured quitting of tobacco in past one year was 
retained and included in the final multivariable regression model, while the one 
measuring quitting of cigarettes in past one year was deleted and was not included in 
any further model analysis. Interaction terms were also tested in the model. However, 
all of the interaction terms were found to be insignificant and hence, were not included 
in the final multivariable model analysis. 
Next, a Hosemer- Lemeshow goodness of fit test was conducted in order to check 
whether the model we assumed was specified correctly and that there was no conflict 
between data and the assumptions made by the model. P-values from this test vary 
between 0 and 1, higher number indicating a better fit, while lower values would indicate 
that model is not acceptable.79 For this study, a P- value of 0.9596 was obtained after 
incorporating sociodemographic predictors, indicating good fit for the specified model 
with the data. 
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All statistical tests were performed in SAS version 9.4 with a two-sided significance of 
0.05 level.   
3.2: Results  
Aim 1A: To estimate the prevalence for current e-cig users and ever e-cig users 
among individuals with COPD  
A total of 7,434,218 (3.10%) individuals were identified from the 2014 NHIS data who 
reported of having been diagnosed with COPD according to their physicians. Further, 
among individuals with COPD, around 642,848 (8.65%) individuals reported of using e-
cigs currently, while the rest 91.35% were not using e-cigs device currently. Next, 
among individuals with COPS, around 1,793,828 (24.37%) reported of having used e-
cigs device in the past, while the rest 75.63% did not use them in the past. Table 3 and 
Figure 1 represents the estimates by e-cig user category among individuals with 
COPD. The chi-squared test results were also significant by e-cig user category 
indicating that both; current e-cig users and ever e-cig users are statistically 
independent. 
Table 3: Prevalence estimates for current e-cig users and ever e-cig users among 
individuals with COPD in the US; NHIS 2014 data estimates 
E-cig user category 
Weighted 
frequency (%) 
Std. error 
of percent 
Rao-Scott 
Chi-square 
test 
P-value 
Current e-cig users     
Yes 642,848 (8.65) 0.9557 
591.99 
 
<0.0001 
 
No 6,791,370 (91.35) 0.9557 
Ever e-cig users  24.37   
Yes 1,793,828 (24.37) 1.2619 
108.38 
No 5,566,982 (75.63) 1.2619 
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Figure 1: Prevalence estimate chart for current e-cig users and ever e-cig users 
among individuals with COPD 
 
 
 
 
 
 
 
 
Aim 1B: To identify the sociodemographic predictors for current e-cig users 
among individuals with COPD  
Sociodemographic predictors were examined among current e-cig users and having 
diagnosed with COPD. Percentages for currently using e-cigs were found to be higher 
among women (62%), whites (90%), between 45-64 years of age (57%), being 
divorced/separated (36%), being overweight/obese (74%), currently not working (88%), 
working for private firm or self-employed (78%), currently smoking cigarettes (68%), 
currently not smoking tobacco products (81%), currently not using smokeless tobacco 
products (65%), and have tried quitting tobacco in past one year for more than one 
day(62%) (Table 4). Additionally, those who resided in the south region of the US were 
the ones who were currently using e-cigs device in higher proportion (54%) in 
comparison to the current e-cigs device usage from all other US regions (Figure 2). All 
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the sociodemographic variables were analyzed for the test for equal proportions with the 
help of chi-square test. The test results were highly significant (P < 0.0001) among all 
the current e-cig user variable categories indicating that there exist statistical 
independence among each of the sociodemographic variables being tested. 
Table 4: Sociodemographic characteristics for current e-cig users among 
individuals with COPD  
Sociodemographic 
characteristics  
Weighted N (%) 
Std. 
error 
Rao-Scott 
Chi-square 
test 
P-value 
Sex         
Men 244,914(38.10) 2.36 
24.19 <0.0001 
Women 397,934(61.90) 2.36 
Age (years)         
18-44 30,833(4.79) 0.1361 
705.37 <0.0001 45-64 366,213(56.96) 1.6599 
>= 65 245,802(38.24) 1.6082 
Race         
White 559,134(90.37) 0.167 
20429.99 <0.0001 
African American 59,551(9.62) 0.167 
Marital Status         
Married  165,885(27.75) 2.24 
101.78 <0.0001 Widowed 160,160(26.79) 1.13 
Divorced/Separated 214,300(35.85) 1.37 
Never married 57,294(9.58) 1.21     
BMI         
Normal 164,999(26.02) 2.48 
72.62 <0.0001 
Overweight/Obese 469,051(73.97) 2.48 
Region         
Northeast 61,233(9.52) 0.4384 
1790.58 <0.0001 
Midwest 194,688(30.28) 1.01 
South 346,413(53.88) 1.144 
West 40,514(6.3) 0.3511 
Working status         
Currently working 80,340(12.49) 0.8029 
962.78 <0.0001 
Currently not working 562,508(87.5) 0.8029 
Type of employment         
Private firm/Self-employed 496,088(77.73) 1.32 304.51 <0.0001 
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Federal/State/Local 
government employee 142,095(22.26) 
1.32 
Smoking status         
Current smokers 435,592(68.48) 1.65 
109.11 <0.0001 
Former smokers 200,410(31.51) 1.65 
Currently smoking tobacco 
products other than cigarettes 
every day or some days   
      
Yes 33,250(18.59) 0.2249 
12123.58 <0.0001 
No 145,521(81.4) 0.2249 
Currently using smokeless 
tobacco products every day 
or some days   
      
Yes 38,502(35.43) 0.19 
5603.19 <0.0001 
No 70,165(64.56) 0.19 
Tried quitting smoking past 
one year more than one day   
      
Yes 242,512(55.67) 1.37 
17.11 <0.0001 
No 193,080(44.32) 1.37 
Tried quitting tobacco past 
one year more than one day   
      
Yes 360,013(62.2) 2.01 
34.84 <0.0001 
No 218,717(37.79) 2.01 
 
Figure 2: Percentage of adults with COPD who currently use e-cigs by region: 
NHIS 2014 estimates 
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Further, percentages of current e-cig users among individuals with COPD were 
estimated by age and by gender status (Figure 3), and by race and by gender status 
(Figure 4). Percentages for current e-cig device use was higher for individuals between 
45-64 years of age in total and among whites in total. Percentages of current e-cig 
users were higher for women over men among all different age groups (Figure 3) and 
among both races (Figure 4). Next, percentages for e-cigs usage, both for current users 
and ever users, were calculated by smoking status (Figure 5) and by cigarette quitting 
status (Figure 6). Among current users and ever e-cig users (Figure 5), 68% and 77% 
of them were currently smoking cigarettes, respectively. Similarly, among current e-cig 
users and ever e-cig users (Figure 6), 56% and 58% of them have tried using these 
devices to help them quit smoking respectively.  
Figure 3: Percentage of adults with COPD who are currently using e-cigs by age 
and gender: NHIS 2014 estimates  
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Figure 4: Percentage of adults with COPD who are currently using e-cigs by race 
and gender: NHIS 2014 estimates 
 
Figure 5: Percentage of adults with COPD who are currently using and have ever 
tried using e-cigs by smoking status: NHIS 2014 estimates 
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Figure 6: Percentage of adults with COPD who are currently using and have ever 
tried using e-cigs by quitting smoking status: NHIS 2014 estimates 
 
  
Aim 1C. To examine the association between current e-cig users and 
sociodemographic predictors among individuals with COPD 
Bivariate logistic regression analysis results (Table 5) found that the current e-cig use 
was significantly associated with age (P = 0.0155), with marital status (P = 0.001), with 
region of residence (P = 0.0003), with smoking status (P < 0.0001), with working status 
(P = 0.0147), with current use of smokeless tobacco products either every day or some 
days (P < 0.0001), and with tobacco quitting status in past one year (P = 0.0001). The 
odds of using e-cig device currently among individuals with COPD were higher for 
individuals between 45-64 years of age (OR: 1.766; 95% CI: 1.119, 2.785), residing in 
south (OR: 3.893; 95% CI: 1.990, 7.619), currently smoking cigarettes (OR: 3.051; 95% 
CI: 1.963, 4.740), currently using smokeless tobacco products every day or some days 
8.7
24.4
55.67
58.08
44.3
41.9
0
10
20
30
40
50
60
70
Current e-cig users Ever e-cig users
P
e
rc
e
n
t
E-cig user status
Total Tried quitting smoking once Didn’t try
 
 
78 
 
(OR: 1.967; 95% CI: 1.50, 2.580), and among those who have tried quitting the use of 
tobacco in past one year for more than one day (OR: 2.345; 95% CI: 1.525, 3.603). The 
odds of using e-cigs device currently among individuals with COPD were also found to 
be higher for women, with African American race, widowed, divorced/separated, 
overweight/obese, working with private-firm/self-employed, currently smoking tobacco 
products other than cigarettes every day or some days, and have tried quitting smoking 
past one year more than once. However, the association was not statistically significant 
at the significance level of 0.05. 
Table 5: Characteristics associated with current e-cig use among COPD patient 
population (bivariate logistic regression analysis). Significant results highlighted 
in bold  
Socio-demographic variables 
Unadjusted analysis 
Odds 
ratio 
95% Wald CI P-value 
Sex       
Men 0.742 0.469,1.175 0.203 
Women  Reference  
Age (years)     0.0155 
18-44 0.815 0.335, 1.985 0.2471 
45-64 1.766 1.119,2.785 0.0081 
>= 65  Reference  
Race     0.5903 
White 0.765 0.289,2.027 0.5903 
African American  Reference  
Marital Status     0.001 
Married  0.526 0.249,1.113 0.001 
Widowed 1.391 0.724,2.675 0.0612 
Divorced/Separated 1.536 0.822,2.868 0.0094 
Never married Reference 
BMI     0.7602 
Normal 0.928 0.575,1.498 0.7602 
Overweight/Obese Reference 
Region     0.0003 
Northeast 1.503 0.557,4.055 0.2972 
Midwest 3.33 1.522,7.290 0.0494 
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South 3.893 1.990,7.619 0.0008 
West Reference 
Smoking status     <0.0001 
Current smokers 3.051 1.963,4.740 <0.0001 
Former smokers Reference 
Working status     0.0147 
Currently working 0.456 0.243,0.857 0.0147 
Currently not working Reference 
Type of employment     0.3259 
Private firm/Self-employed 1.26 0.795,1.996 0.3259 
Federal/State/Local government 
employee 
Reference 
Currently smoking tobacco products other 
than cigarettes every day or some days 
    0.1144 
Yes 1.484 0.909, 2.424 0.1144 
No Reference 
Currently using smokeless tobacco products 
every day or some days 
    <0.0001 
Yes 1.967 1.50, 2.580 <0.0001 
No Reference 
Tried quitting smoking past one year more 
than one day 
    0.4029 
Yes 1.225 0.761,1.972 0.4029 
No Reference  
Tried quitting tobacco past one year more 
than one day 
    0.0001 
Yes 2.345 1.525,3.603 0.0001 
No Reference  
 
Further, multivariate logistic regression analysis was performed to find out the 
association between current e-cig use and sociodemographic predictors among 
individuals with COPD (Table 6).  Out of all the variables included in the final model, the 
association between current use of e-cigs and having tried quitting tobacco in the past 
one year for more than one day was found to be significant (OR: 2.042; 95% CI: 1.051, 
3.971; results from the model with cluster analysis and with relevant variables). The 
odds of using e-cigs device currently among individuals with COPD were also found to 
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be higher for white men, with age over 65, widowed, divorced/separated, 
overweight/obese, residing in south, currently not smoking cigarettes, currently not 
working, and if working; then working for Federal/State/Local government employee. 
However, the association was not statistically significant at the significance level of 0.05. 
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Table 6: Characteristics associated with current e-cig use among individuals with COPD (Multivariate logistic 
regression analysis). Significant results highlighted in bold  
Socio-demographic variables Adjusted analysis with cluster and with few variables 
 Odds ratio 95% Wald CI P-value 
Sex       
Men 0.762 0.432, 1.346 0.3491 
Women Reference 
Age (years)       
18-44 0.74 0.193, 2.833 0.7456 
45-64 0.789 0.384, 1.623 0.7423 
>= 65 Reference 
Race       
White 1.211 0.801, 1.832 0.3639 
African American Reference 
Marital Status    0.0094 
Married  0.613 0.317, 1.186 0.0016 
Widowed 1.932 0.819, 4.557 0.0296 
Divorced/Separated 1.298 0.695, 2.422 0.331 
Never married Reference 
BMI       
Normal 0.657 0.368, 1.172 0.1549 
Overweight/Obese       
Region     0.1957 
Northeast 1.242 0.393, 3.928 0.5786 
Midwest 1.975 0.873, 4.468 0.3449 
South 2.33 1.028, 5.283 0.0965 
West Reference 
Smoking status       
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Current smokers 0.546 0.239, 1.247 0.1509 
Former smokers Reference 
Working status       
Currently working 0.589 0.323, 1.072 0.0833 
Currently not working Reference 
Type of employment       
Private firm/Self-employed 0.975 0.539, 1.763 0.9326 
Federal/State/Local government employee Reference 
Tried quitting tobacco past one year more than one 
day 
      
Yes 2.042 1.051, 3.971 0.0353 
No Reference 
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3.3: Discussion 
The COPD prevalence in the United States using the 2014 NHIS survey data was 
estimated to be 3.10%. This estimate was slightly lower than the estimates in a similar 
study conducted by Doney et al.80 According to this study, the estimated prevalence for 
COPD was found to be 4.2% (95% CI: 4.0% to 4.3%). This study estimated the 
prevalence among COPD individuals using 2004-2011 NHIS data and included only 
working adults from age 40 years till 70 years old. The difference in the type of 
population included in our study and the study by Doney et al. could be the main reason 
in the differences in the prevalence estimates. The prevalence is usually higher among 
a working population, where it is attributable mainly due to occupational exposure.81 
Further, in a study conducted by CDC, the age adjusted total prevalence among adults 
aged 18 and over for chronic bronchitis was found to be 3.6%, while the age adjusted 
prevalence for emphysema was found to be 1.3% for the year 2015. These estimates 
came from the NHIS survey date and were very similar to the estimates from our 
study.82 
The prevalence estimates for current e-cig users and ever e-cig users among 
individuals with COPD were found to be 8.65% and 24.37% respectively. To our 
knowledge, this is the first study to report the prevalence for current and ever e-cig 
users among individuals with COPD. All other studies have reported prevalence for 
current and ever e-cig users among general population residing in the US.38 The 
estimates in the study by Syamlal G. et al. comes from the same year and same data 
source as ours with the only difference in the study population being evaluated. In the 
study findings by Syamlal G. et al., the prevalence of ever e-cig users among US 
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working adults aged ≥ 18 years was found to be 12.6%. While for this study, the 
prevalence of ever e-cig users among COPD adults were two times higher than the 
study estimate by Syamlal G. et al. Similarly, the prevalence of current e-cig users 
among general population was 3.7%, while for this study it was nearly two times higher 
among COPD individuals. The differences in these estimates indicates a higher use of 
e-cig devices among disease individuals than the general population. Since e-cig 
devices have been encouraged to help in quitting smoking, and are also marketed as an 
alternative to smoking in places where tobacco smoking is prohibited,25 the uptake for 
these devices may have increased among disease population either for trying to quit 
smoking or as an alternative to smoking in the places where it is prohibited.  
Further, descriptive analysis results found the percentage of current e-cigs use among 
COPD adult individuals was higher among women (62%), among whites (90%), among 
individuals between 45-64 years of age (57%), among current smokers (68%), and 
among those who have tried quitting smoking in the past for more than one day (62%). 
The estimates were in agreement with the results from the study done by Schoenborn 
et al.,83 where the proportion of current e-cig users among general adult population 
were higher among current smokers (16%) and among those who had tried quitting 
smoking in the past (22%) in comparison to former smokers (2%) and never smokers 
(0.4%). While our study results were not in agreement with the estimates of current e-
cig users among general population by gender, by race and by different age groups. 
The proportion of current usage for e-cig devices among the general population were 
found to be same for men and women, and higher among non-Hispanic American 
Indian Alaska Native adults.  
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The reason for such observed differences in e-cigs usage could be due to the fact the 
prevalence of COPD among women is higher than in men and there exists differences 
in the management to this disease.84 Also, tobacco users among women have 
increased in comparison to men and they have greater difficulties in quitting smoking. 
This might explain the higher use of e-cig devices among women in comparison to 
males. Also as the prevalence of COPD is higher among individuals with age 45 and 
above, among those unemployed and among those who are divorced/separated, this 
again may be correlated with higher usage of e-cig devices in present.11  
Further, the results from bivariate logistic regression analysis found an association for 
the current use of e-cigs with those currently smoking cigarettes, have tried quitting 
smoking in the past, and are currently using smokeless tobacco products. These 
estimates were in agreement to the findings from the study by Schoenbron et al. This 
indicates the possible connection for current smokers with COPD trying to use e-cigs 
devices for quitting smoking.  
This study possesses several weaknesses. First, since the prevalence estimates for 
COPD were based on the self-reported diagnoses by physician and as NHIS doesn’t 
collect the information related to spirometry or any other medical or laboratory data, the 
estimates for COPD may be under- or over-reported. Second, the prevalence estimates 
for current and ever e-cig users were also based on the self-report and have not been 
validated like self-reported smoking status. Hence, it questions the accuracy for self-
reported e-cigs use. Third, since NHIS data doesn’t include institutionalized individuals, 
it misses out the sections of population such as military personnel, and older adults 
living in nursing homes and other long-term care facilities. This may further lead to 
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under or over-estimates for COPD, current and ever e-cig usage.85 Fourth, due to small 
sample sizes among subpopulations, it restricted the precision of estimates. Fifth, 
because of the cross-sectional study design, and estimates based on the annual 
sample, results cannot be seen as causal. Finally, NHIS data possess the potential for 
self-selection bias. The participation rate for the survey respondents for the year 2014 
was only 58.9%. Since this data doesn’t capture the information from non-respondents, 
it is difficult to tell whether the survey respondents differed from non-responders in a 
significant manner. 
However, this study possess many strengths. First, to our knowledge, this is the first 
study to estimate the prevalence, identify characteristics and asses the association 
between current e-cig users and sociodemographic predictors among individuals with 
COPD. Second, the study was performed using the large sample size, population-based 
data among non-institutionalized civilian individuals. Hence the results from this study 
may be generalizable to the COPD disease population in the US. Additionally, since 
NHIS survey data have been utilized for research purpose and in policymaking, the 
results from this study can be used as point of reference for further studies or in 
healthcare decision making. 
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Chapter 4: Specific Aim 2 
Aim 2: To examine the predictors and estimate the total healthcare cost among 
current smokers with COPD in the US 
D. To examine the sociodemographic and clinical characteristics among current 
smokers with COPD 
E. To estimate the unadjusted total, direct and indirect healthcare cost among current 
smokers with COPD 
F. To estimate the adjusted total, direct and indirect healthcare cost among current 
smokers with COPD 
4.1: Methods 
Design: Retrospective, cross-sectional design 
Data 
The Medical Expenditure Panel Survey (MEPS) data was utilized for this study. This 
dataset provides nationally representative estimates of the US non-institutionalized 
civilian population, with oversampling of blacks and Hispanics.86 The survey data is 
collected through in-person interviews of families and individuals, their medical 
providers, and employers in the US and provides information on sociodemographic and 
economic characteristics, employment, income, health status, health insurance 
coverage, health conditions, payments and charges, medical services utilization, access 
to care, and medical conditions and procedures that were self-reported by the 
participants. The survey consists of three main components: household component 
(HC), medical provider component, and insurance component. For this study, HC files 
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were utilized. Data from the years 2012 and 2013 were used for this study. Data from 
both years were aggregated by using the common variance structure within MEPS 
complex survey design in order to ensure compatibility and comparability of study 
variables and to increase the precision of the estimates.87,88 
Study population 
The study population consisted of US non-institutionalized civilian population with age ≥ 
18 years, and being alive during the study period. Further, we included only those 
individuals who self-reported of having diagnosed with COPD. COPD status were 
identified using the International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes 491 (chronic bronchitis), 492 (emphysema) and 496 
(chronic obstructive airway disease, not elsewhere classified) from the medical 
conditions file. The medical conditions and procedures self-reported by survey 
participants are professionally coded to fully specified 5-digit ICD-9-CM codes. To 
protect participant’s confidentiality, MEPS data collapses these 5-digit ICD-9-CM codes 
to 3-digit ICD-9-CM codes.89 Our pooled sample consisted of 3,668 adults 18 years and 
older and alive during the calendar year, representing an annually weighted population 
of 18,936,800. The average response rate for participants from both years was 54.55% 
(52.8% - 56.3%).90  
Study variables 
Our main independent variable for this study was current smoking status among the 
survey participants. MEPS captures this information by asking participants whether they 
currently smoke or not. The response to this survey questionnaire was categorized as 
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Yes/No. Moreover, relevant sociodemographic and clinical variables were also included 
in this study based on the Anderson Behavior and Utilization Model for Health Service 
Use to identify the potential independent factors related to total healthcare cost.91 
Variables were classified into three major components: predisposing factors, enabling 
factors and need factors. Individual predisposing factors included age in years (18-44, 
45-64, 65+), gender (male, female), race/ethnicity (white, African-American, Latino, and 
other), marital status (married, widowed, separated/divorced, and never married), and 
census defined region categories (Northeast, Midwest, South, West). Enabling factors 
included were income (poor, near poor, middle income, and high income according to 
the federal poverty line), type of health insurance (private, public, and uninsured) 
education (less than high school, high school, and college or more), employment status 
(employed and not employed). Need factors included were participant’s clinical 
characteristics such as perceived physical health status (excellent/very good, good, and 
fair/poor), Body Mass Index status (underweight, normal, overweight, and obese), 
number of chronic conditions (≥ 1, none), presence of particular comorbid conditions. 
Comorbid conditions included were presence of clinical conditions such as 
cardiovascular and other circulatory disorders, depression and other mental disorders, 
diabetes and other endocrine disorders, and arthritis and other musculoskeletal 
disorders.  
The key dependent variable for this study was the total healthcare cost per person per 
year, which included both direct and indirect cost. Direct costs are the healthcare costs 
associated with direct patient-care services.92 They include hospital inpatient, physician 
inpatient, physician outpatient, emergency department outpatient, nursing home care, 
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hospice care, rehabilitation care, specialists’ and other health professionals’ care, 
diagnostic tests, prescription drugs and drug sundries, and medical supplies. The 
source of this payment includes direct payment from individuals, through private 
insurance, through Medicaid, through Medicare and other sources for each calendar 
year.93 For this study, direct costs were classified as inpatient, outpatient, prescription, 
emergency room, and other. Other costs included home health, vision, hearing devices, 
prosthesis, durable medical equipment, disposable supplies, orthopedic items, 
ambulance services, alterations/modifications, bathroom aids, medical equipment, and 
other miscellaneous items that were rented, purchased, or obtained during the study 
timeline.  Indirect cost refers to the costs associated with the impact of disease on 
patients or caregivers economic output.94  
Indirect costs were estimated using the human capital approach which assumes 
productivity to be valued at the individual’s market earnings.94 Productivity loss 
(morbidity) consisted of the work days missed to stay in bed due to COPD. Hourly wage 
for patients were multiplied by 8 (assuming 8 hours work day) to get the daily wage. 
This was then multiplied by the number of workdays missed by those with COPD in 
order to calculate the total productivity loss due to COPD. In this study indirect 
productivity loss due to mortality were not examined as we included only those patients 
that were alive during the calendar year. Total healthcare costs were then calculated by 
summing both direct and indirect healthcare cost. All healthcare cost data were adjusted 
to 2016 dollar value using the healthcare consumer price index for medical care 
services obtained from the Bureau of Labor Statistics.95 
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Statistical analysis 
Prevalence estimates for current smokers and non-current smokers among individuals 
with COPD were calculated using the survey sample weights in order to represent the 
estimates at the national level. Further, descriptive statistics (weighted frequency, %, 
std.error) were calculated to describe the sociodemographic and clinical characteristics 
among current and non-current smokers with COPD. Differences in proportion of 
individuals for each predisposing, enabling and need factors were also reported 
between both groups using Rao-Scott Chi square test at the significance level of 0.05. 
Further, unadjusted annual mean total, direct and indirect healthcare cost for current 
smokers and non-current smokers were calculated among individuals diagnosed with 
COPD. To estimate the adjusted annual mean total, direct and indirect healthcare cost, 
an econometric or incremental approach was used. This approach estimates the 
difference in cost between a cohort of current smokers with COPD and a cohort of non-
current smokers without COPD. This approach is most appropriate with a large, national 
dataset and is used for risk factors and diseases with several comorbidities. Incremental 
healthcare cost were estimated using two-part model. Two-part models are used when 
an outcome consists of a large number of zero outcomes and a group of nonzero 
outcomes, resulting into the data that is highly skewed to right.96 In modeling of 
healthcare cost, usually some patients have zero costs, while the rest have positive 
costs that are often heavily skewed to the right. Hence, the two-part model (mixed 
discrete-continuous) accounts for the observations having no cost (ie, 0 expenditures) 
and accurately estimates the incremental healthcare cost for current smokers compared 
to noncurrent smokers among individuals with COPD.97 In the first stage, a probit model 
was used to evaluate the probability of having a 0 versus positive healthcare cost. In the 
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second stage, a generalized linear model (GLM) with a log-link is assessed conditional 
on cost for those having a positive healthcare cost. In the adjusted model, we controlled 
for all sociodemographic and clinical characteristics. Post-regression margins provide 
estimates for incremental total, direct and indirect health care cost for current smokers 
compared to non-current smokers among individuals with COPD. 
All of the descriptive analyses were carried out using SAS version 9.4 (SAS Institute 
Inc, Cary, NC), whereas two-part model analyses were carried out using the ‘twopm’ 
command in Stata (Stata-Corp, College Station, TX). Post regression, estimates for 
incremental healthcare cost were derived using the ‘‘margins’’ command in Stata. All 
our analyses accounted for clustering, stratification, complex survey design, and 
sampling weights to evaluate the national healthcare cost estimates for current smokers 
among individuals with COPD. Further, in our analysis we divided the analytic sampling 
weight variable by aggregated number of years to represent the average population size 
per year.98 
4.2: Results  
Aim 2A. To examine the sociodemographic and clinical characteristics among 
current smokers with COPD 
A total of 18,936,800 (12.3%) individuals with age 18 years and above were identified 
from the 2012-2013 MEPS data who were diagnosed with COPD and were alive during 
the study period. Approximately 22% of them were currently smoking, while the rest 
78% were not smoking during the time of the interview (Figure 7). Descriptive analysis 
for sociodemographic and clinical characteristics for current smokers and non-current 
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smokers among individuals with COPD revealed that there were significant statistical 
differences between both groups when tested at 0.05 level of significance. Further, 
among current smokers with COPD, percentages for current smokers were higher 
among women (59.14%), with race other than white/black/Latino (66.47%), between 45-
64 years of age (47.81%), married (38.41%), having college or higher degree (39.78%), 
with poor/near poor income (52.82%), unemployed (58.49%), with private insurance 
(46.62%), residing in south (39.18%), being obese (43.15%), with perceived physical 
health status as fair/poor (46.39%), having 1 or more chronic conditions (70.27%), 
having diagnosed with arthritis and other musculoskeletal disorders (53.72%), and 
having diagnosed with cardiovascular and other circulatory disorders (50.29%). (Table 
7 and Table 8). 
Figure 7: Percent of COPD individuals by current smoking status; MEPS 2012-
2013 data estimates 
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Table 7: Description of sociodemographic characteristics among COPD patient population by current smoking 
status; Medical Expenditure Panel Survey 2012-2013 
Sociodemographic 
variables 
COPD sample 
population 
Currently 
smoking 
Not currently 
smoking 
chisqval Chisq 
p-
value 
Significance  
Weighted N Weighted N (%) Weighted N (%) 
18,936,800 3,901,575(2.7) 13,653,006(9.60) 
Age 
      
18-45 6,600,000 1,340,000(34.26) 4,680,000(34.24)  
160.411 
0.000 *** 
45-64 6,980,000 1,870,000(47.81) 4,600,000(33.70) 0.000 *** 
65+ 5,360,000 700,000(17.93) 4,380,000(32.06) 
  
Gender 
      
Women 11,900,000 2,310,000(59.14) 8,760,000(64.15)  
85.600 
0.000 *** 
Men 6,990,000 1,590,000(40.86) 4,890,000(35.85) 0.051 
 
Race/Ethnicity 
     
White 4,870,000 1,120,000(28.58) 3,510,000(25.69)  
49.558 
0.000 *** 
Blacks 694,000 119,000(3.05) 513,000(3.76) 0.090 
 
Latino 606,000 73,987(1.90) 493,000(3.61) 
  
Other 12,800,000 2,590,000(66.47) 9,140,000(66.94) 
  
Marital status 
      
Married 9,220,000 1,500,000(38.41) 7,140,000(52.31)  
331.685 
0.000 *** 
Widow 1,880,000 365,000(9.35) 1,400,000(10.23) 0.000 *** 
Separated/Divorced 3,500,000 1,150,000(29.55) 2,130,000(15.60) 
  
Never married 4,340,000 885,000(22.69) 2,990,000(21.87) 
  
Education status       
< High school 3,970,000 1,260,000(33.34) 2,300,000(17.35)  
272.587 
0.000 *** 
High school 4,200,000 1,020,000(26.88) 2,930,000(22.09) 0.000 *** 
College or more 10,200,000 1,510,000(39.78) 8,030,000(60.56) 
  
Income FPL 
      
Poor 3,130,000 1,150,000(29.56) 1,770,000(12.97)  
410.065 
0.000 *** 
Near Poor 3,640,000 908,000(23.26) 2,500,000(18.30) 0.000 *** 
Middle Income 5,390,000 1,090,000(27.94) 3,910,000(28.61) 
  
High Income 6,770,000 750,000(19.24) 5,480,000(40.12) 
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Employment status 
      
Employed 9,430,000 1,620,000(41.51) 7,090,000(51.95) 1.471 0.225 
 
Not employed 9,510,000 2,280,000(58.49) 6,560,000(48.05) 0.000 *** 
Health insurance type 
      
Private 11,800,000 1,820,000(46.62) 9,220,000(67.51)  
266.278 
0.000 *** 
Public 5,450,000 1,500,000(38.53) 3,520,000(25.75) 0.000 *** 
Uninsured 1,650,000 580,000(14.86) 919,000(6.73) 
  
Census region 
 
 
    
Northeast 3,890,000 716,000(18.53) 2,790,000(20.46)  
46.091 
0.000 *** 
Mid-west 4,200,000 1,080,000(27.86) 2,850,000(20.90) 0.004 ** 
South 6,930,000 1,530,000(39.18) 4,940,000(36.21) 
  
West 3,920,000 577,000(14.79) 3,060,000(22.43) 
  
Asterisks represent significant group differences in healthcare cost, on the basis of chi-square test. 
*.01 # P < .05, **.001 # P < .01, ***P < .001. 
 
Table 8: Description of clinical characteristics among COPD patient population by current smoking status; 
Medical Expenditure Panel Survey 2012-2013 
Sociodemographic 
variables 
COPD sample 
population 
Currently 
smoking 
Not currently 
smoking 
chisqval Chisq 
p-
value 
Significance  
Weighted N Weighted N (%) Weighted N (%) 
18,936,800 3,901,575(2.7) 13,653,006(9.60) 
Physical health status       
Excellent/very good 7,410,000 855,000(21.90) 5,950,000(43.59) 
218.984 
0.000 *** 
Good 5,810,000 1,240,000(31.71) 4,200,000(30.73) 0.000 *** 
Fair/poor 5,720,000 1,810,000(46.39) 3,510,000   
Number of chronic 
conditions 
      
>=1 12,500,000  2,740,000(70.27) 9,050,000(66.27) 
6.973 
0.008 ** 
None 6,410,000 1,160,000(29.73) 4,600,000(33.73) 0.143  
Selected 
comorbidities  
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Cardiovascular and 
other circulatory 
disorders 
      
Yes 9,180,000 1,960,000(50.29) 6,710,000(49.17) 
27.552 
0.000 *** 
No  9,750,000 1,940,000(49.71) 6,940,000(50.83) 0.727  
Depression and other 
mental disorders 
      
Yes 6,610,000 1790,000(45.84) 4,430,000(32.46) 
143.172 
0.000 *** 
No  12,300,000 2,110,000(54.16) 9,220,000(67.54) 0.000 *** 
Diabetes and other 
endocrine disorders 
      
Yes 3,240,000 761,000(19.51) 2,350,000(17.23) 
26.778 
0.000 *** 
No  15,700,000 3,140,000(80.49) 11,300,000(82.27) 0.293  
Arthritis and other 
musculoskeletal 
disorders 
      
Yes 8,960,000 2,100,000(53.72) 6,400,000(46.85) 
1.515 
0.218  
No  9,970,000 1,810,000(46.28) 7,260,000(53.15) 0.012 * 
BMI categorization       
Under weight 278,000 75,402(1.96) 191,000(1.43) 
28.170 
0.000 *** 
Normal 5,150,000 1,040,000(27.14) 3,610,000(26.90) 0.256  
Over 5,730,000 1,070,000(27.75) 4,270,000(31.80)   
Obese 7,440,000 1,660,000(43.15) 5,350,000(39.87)   
Asterisks represent significant group differences in healthcare cost, on the basis of chi-square test. 
*.01 # P < .05, **.001 # P < .01, ***P < .001. 
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Aim 2B. To estimate the unadjusted total, direct and indirect healthcare cost 
among current smokers with COPD 
The unadjusted cost for current smokers and non-current smokers among individuals 
with COPD were calculated using the two-part regression model. The unadjusted 
annual mean per person total, direct and indirect healthcare cost among current 
smokers with COPD were $12,555.20 (SE: $588.30), $11,563.60 (SE: $556.30), and 
$991.60 (SE: $119.50) respectively (Table 9), while the unadjusted annual mean per 
person total, direct and indirect healthcare cost for non-current smokers with COPD 
were $10,968.60 (SE: $558.40), $10,054.30 (SE: $527.60), and $914.30 (SE: $168.60) 
respectively (Table 9).  The unadjusted cost were higher among current smokers with 
COPD in comparison to those not-currently smoking (Figure 8). However, only 
outpatient and emergency room cost were significantly higher for current smokers with 
COPD in comparison to non-current smokers with COPD. Among current smokers with 
COPD, direct healthcare cost comprised of the major total cost (88.23%), where bulk of 
those cost came from outpatient (33.17%) and prescription (32.49%), followed by 
inpatient (28.76%) cost (Table 9). Healthcare cost were also calculated by age and 
gender, as men and women use healthcare resources differently to meet their disease 
demands. The unadjusted total, direct and indirect healthcare costs were found to be 
higher for women when compared to men among current smokers with COPD (Figure 
9). Among men, cost were higher for individuals with age 65 years and above, while for 
women, total cost were higher for individuals between 45 and 64 years of age (Table 
10). 
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Figure 8: Unadjusted total, direct and indirect healthcare cost among individuals 
with COPD by current smoking status; Medical Expenditure Panel Survey 2012-
2013 
 
Figure 9: Unadjusted healthcare cost for current smokers among individuals with 
COPD by age and gender status; Medical Expenditure Panel Survey 2012-2013 
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Table 9:  Unadjusted annual mean (SE) healthcare cost per person by current smoking status among individuals 
with COPD; Medical Expenditure Panel Survey 2012-2013 estimates 
Unadjusted annual mean (SE) healthcare cost per patient 
 Healthcare Cost Current smokers Not currently smoking 
Mean (SE) 95% CI Mean 95% CI 
Direct Cost $11,563.60 ($556.30) [10466.8 , 12660.4] $10,054.30($527.60) [ 9013.9 , 11094.6] 
Inpatient $3,057.90 ($300.50) [ 2465.3 ,  3650.4] $2,182.20($305.50) [ 1579.8 ,  2784.6] 
ER $366.00 ($29.40) [  308.1 ,   423.9] $545.50($55.20) [  436.8 ,   654.3] 
Outpatient $3,756.30 ($274.70) [ 3214.6 ,  4297.9] $2,622.90($200.20) [ 2228.3 ,  3017.6] 
Prescription $3,325.50 ($209.40) [ 2912.6 ,  3738.4] $3,805.60($268.20) [ 3276.8 ,  4334.5] 
Others $1,058.00 ($98.70) [  863.4 ,  1252.5] $897.90($150.50) [  601.3 ,  1194.6] 
Indirect Cost $991.60 ($119.50) [  755.8 ,  1227.4] $914.30($168.60) [  581.5 ,  1247.0] 
Total $12,555.20 ($588.30) [11946.1 , 14265.8] $10,968.20($558.40) [10315.1 , 12517.2] 
 
Table 10: Unadjusted annual mean (SE) healthcare cost per person among current smokers with COPD by age 
and gender; Medical Expenditure Panel Survey 2012-2013 estimates 
Unadjusted annual mean (SE) healthcare cost per patient 
 Healthcare cost by 
different age group   
Men Women 
Mean (SE) 95% CI Mean 95% CI 
Total cost         
18-44 $5,091.53($1,147.99) [2828.08, 7354.99] $7,689.67 ($705.67) [6298.32, 9081.01] 
45-64 $12,164.00 ($1,592.15) [9025.18, 15303.5] $17,359.00($1,771.08) [13867,20851.33] 
65+ $18,142.00($1,328.02) [15523.16, 20760] $16,384.00($1,216.57) [13985.4,18782.7] 
Direct cost         
18-44 $4,479.89 ($1,106.14) [2298.96, 6660.81] $6,379 ($613.10) [5170.28, 7587.94] 
45-64 $10,651.00($1,499.10) [7695.01,13606.45] $15,407 ($1,661.38) [12131.68,18683] 
65+ $16,258.00 ($1,235.13) [13822.38,18692.8] $14,678 ($1,159.42) [12392,16964.29] 
Indirect cost         
18-44 $646.85 ($177.09) [297.48, 996.23] $898.62($227.17) [450.45, 1346.80] 
45-64 $1,656.46($551.34) [568.74, 2744.17] $1,086.89 ($153.73) [783.61, 1390.17] 
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Aim 2C: To estimate the adjusted total, direct and indirect healthcare cost among 
current smokers with COPD  
The adjusted cost for current smokers and non-current smokers among individuals with 
COPD were calculated using the two-part regression model. The adjusted incremental 
total annual average cost among current smokers with COPD were significantly higher 
by $1,811.70 (P = 0.015) (Table 11) when compared to those not currently smoking. 
Further, the adjusted incremental total annual average cost among current smokers with 
COPD were higher significantly for women ($1,719.80), with age 65 and above 
($5,134.03), having college or higher degree ($3,780.46), unemployed ($3,618.21), 
covered through private insurance ($7,259.76), having perceived physical health status 
as fair/poor ($8,568.66), with 1 or more chronic conditions ($3,579.41), having 
depression and other mental disorders ($4,070.06), having diabetes and other 
endocrine disorders ($3,067.80), and having arthritis and other musculoskeletal 
disorders ($2,593.07). (Table 11). The adjusted total, direct and indirect healthcare cost 
among current smokers with COPD were $12,441.67, $10,972, and $145.13 
respectively (Table 12).  Out of the total cost estimates, direct cost comprised major 
part of the cost (88%), with majority of those direct cost coming from prescription 
(31.63%), outpatient (31%), and inpatient cost (25.65%).  Adjusted healthcare cost were 
also calculated by age and gender status. The adjusted incremental total, direct and 
indirect healthcare cost were found to be higher for women ($1,901) among current 
smokers with COPD in comparison to non-current smokers with COPD (Table 13). The 
adjusted incremental total, direct and indirect healthcare cost were found to be higher 
for men ($1,649) among current smokers with COPD in comparison to non-current 
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smokers with COPD (Table 13). Among men, cost were higher for individuals with age 
65 years and above ($2,049). Among women, cost were higher for individuals with age 
over 45 years ($1,800). 
Table 11: Two-part regression model: incremental total healthcare cost by current 
smoking status among US adults with COPD accounting for sociodemographic 
and clinical characteristics adjusted to 2016 dollars 
Sociodemographic and 
clinical variables 
Adjusted annual mean (SE) healthcare cost per COPD 
patient 
Incremental cost 95%  CI P-value 
Constant $12441.67 $11684.23 $13199.11 0 
Key independent variable         
Not smoking Reference  
Currently smoking $1,811.70 $345.47 $3,277.93 0.015 
Age     
18-45 Reference  
45-64 $3,355.68 $1,546.24 $5,165.13 0 
65+ $5,134.03 $3,081.91 $7,186.15 0 
Gender     
Women $1,719.80 $92.36 $3,347.24 0.038 
Men Reference  
Race/Ethnicity     
White $1,590.79 -$1,434.62 $4,616.21 0.303 
Blacks $2,862.69 -$2,042.96 $7,768.35 0.253 
Latino Reference  
Other $2,013.74 -$700.13 $4,727.63 0.146 
Marital status   
Married -$874.74 -$3,224.01 $1,474.51 0.466 
Widow $416.87 -$2,663.83 $3,497.59 0.791 
Separated/Divorced $9.52 -$3,114.56 $3,133.60 0.995 
Never married Reference  
Education     
< High school Reference  
High school $238.95 -$1,476.68 $1,954.59 0.785 
College or more $3,780.46 $2,033.76 $5,527.63 0 
Income FPL   
Poor $864.69 -$2,285.89 $4,015.29 0.516 
Near Poor $468.69 -$1,989.07 $2,926.47 0.641 
Middle Income -$1,043.07 -$2,925.42 $839.28 0.302 
High Income Reference  
Employment status     
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Employed Reference  
Not employed $3,618.21 $1,717.67 $5,577.44 0 
Health insurance type     
Private $7,259.26 $5,159.26 $9,359.26 0 
Public $3,980.84 $1,992.71 $5,968.98 0 
Uninsured Reference  
Census region   
Northeast $635.74 -$2,166.25 $3,437.74 0.629 
Mid-west Ref  
South -$1,235.81 -$3,120.61 $648.99 0.23 
West -$1,977.63 -$4,010.92 $55.65 0.057 
Physical health status     
Excellent/very good Reference  
Good $3,600.34 $1,957.57 $5,243.12 0 
Fair/poor $8,568.66 $6,830.77 $10,306.55 0 
Number of chronic 
conditions 
    
>=1 $3,579.41 $877.72 $6,281.10 0.009 
None Reference  
Selected comorbidities      
Cardiovascular and other 
circulatory disorders 
    
Yes $1,092.97 -$1,310.74 $3,496.69 0.373 
No  Reference  
Depression and other 
mental disorders 
    
Yes $4,070.06 $2,554.88 $5,585.23 0 
No  Reference  
Diabetes and other 
endocrine disorders 
    
Yes $3,067.80 $1,118.85 $5,016.74 0.002 
No  Reference  
Arthritis and other 
musculoskeletal disorders 
    
Yes $2,593.07 $381.36 $4,804.77 0.022 
No  Reference  
BMI categorization     
Under weight Not estimable due to small sample size 
Normal Reference  
Over $1,863.42 -$26.97 $3,753.81 0.053 
Obese $974.94 -$692.88 $2,642.77 0.252 
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Table 12: Adjusted annual mean (SE) healthcare cost per person among current 
smokers with COPD; Medical Expenditure Panel Survey 2012-2013 estimates 
  
 Cost estimates 
Adjusted 
Mean SE 95% CI 
Total Cost $12,441.67 $386.88 [$11684.23,$13,199.11] 
Direct Cost $10,972.93 $359.75 [$10267.11,$11678.7] 
Inpatient $2,814.72 $205.18 [$2412.58, $3216.86] 
ER $403.41 $23.40 [$357.54, $449.27] 
Outpatient $3,365.52 $173.22 [$3026.00, $3705.03] 
Prescription $3,469.96 $167.42 [$3141.81, $3798.11] 
Others $976.01 $62.47 [$853.57, $1098.46] 
Indirect Cost $145.13 $16.24 [$113.28, $176.97] 
 
Table 13: Adjusted incremental annual mean (SE) total healthcare cost per person 
among current smokers with COPD by age and by gender in comparison to 
nonsmokers; Medical Expenditure Panel Survey 2012-2013 estimates  
 
4.3: Discussion 
This study aimed to estimate the total healthcare costs among current smokers with 
COPD in comparison to non-smokers with COPD. The unadjusted and adjusted total 
Total cost estimates by 
gender and by age 
Mean SE 95% CI 
Men $1649.45 $693.92 [$289.39, $3009.52] 
18-44 $993.769 $486.30 [$40.62, $1946.91] 
45-64 $1538.51 $721.41 [$124.56, $2952.46] 
65+ $2049.35 $908.14 [$269.43,$3829.28] 
Women $1901.00 $785.64 [$370.06, $3431.93] 
                                        
18-44 
$1418.23 $652.28 [$139.77, $2696.69] 
45-64 $1797.23 $823.73 [$182.73, $3411.72] 
65+ $1811.55 $813.35 [$217.40, $3405.70] 
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healthcare costs among current smokers with COPD were found to be higher by $1,586 
and $1,811, respectively in comparison to non-smokers with COPD. The total 
incremental healthcare costs among current smokers with COPD for this study was 
estimated to be $7.06 billion per year. The average adjusted total healthcare costs 
among current smokers with COPD were estimated to be $14,252 per patient per year. 
Direct healthcare costs comprised of the major component to the total healthcare costs 
spending. Among direct healthcare costs, outpatient and prescription costs consisted of 
the major percentages, followed by inpatient, ER and other healthcare costs. 
Further, the unadjusted and adjusted total healthcare costs were found to be higher 
among women in comparison to men. Additionally, the unadjusted and adjusted total 
healthcare costs were found to be higher among individuals with age 65 & above in 
comparison to individuals between 18 and 64 years of age group. The reason might be 
due to the presence of multiple chronic conditions among this age group and the costs 
associated in treating those chronic conditions.   
 The prevalence for COPD using 2012-2013 MEPS survey data was estimated to be 
12.3%. This estimate was higher in comparison with the results using NHIS and BRFSS 
database in this study. The prevalence estimates for COPD using NHIS and BRFSS 
databases were found to be 3.1% and 6.3% respectively. Difference in prevalence 
estimates might be due to the differences in sampling designs and data collection 
procedures associated with each survey data. Although all of the three surveys captures 
respondents self-report in order to measure health service utilization and health 
characteristics, the differences in prevalence estimates might be due to difference in 
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wordings of the survey questionnaire or differences in the understandings of survey 
participants and also differences in the style of conducting survey.  
To our knowledge this is the first in kind study that have estimated the adjusted and 
unadjusted total healthcare cost among current smokers with COPD in comparison to 
non-smokers with COPD. All of the studies till now have estimated healthcare costs 
among COPD, but haven’t estimated the cost estimates separately for those who were 
currently smoking cigarettes. Also, in our analysis we adjusted for all the relevant 
sociodemographic and clinical characteristics that were thought to be of practical 
significance. Further, all our costs estimates were calculated using two-part model 
where we accounted for both zero and positive expenditures. In addition, the estimates 
from this study are generalizable as the sample from the study was nationally 
representative of the US institutionalized population.   
However, this study have few limitations. First, due to cross-sectional nature of this 
study, it doesn’t help establish temporality. It can only identify an association for 
sociodemographic and clinical characteristics with total healthcare costs. In order to 
establish casualty, it’s essential to conduct a longitudinal study design. Second, s ince 
MEPS collects information on clinical condition through self-reported survey, it possess 
threats related to self-recall bias and self-selection bias. Also, the information for this 
survey comes from self-report, it may possess errors related to coding of clinical 
conditions or can have misclassification bias, hence COPD prevalence estimates and 
current smoking activity may be under reported or over reported. Third, although MEPS 
identifies all pharmacy refills of individuals with COPD, it doesn’t capture the information 
on over the counter medication use, hence prescription estimates could be 
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underestimated. Finally, MEPS doesn’t capture the information for institutionalized 
individuals. Hence, this may lead to underestimation of prevalence for COPD and 
current smoking activity among disease population.  
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Chapter 5 
Aim 3: To estimate the economic impact of adopting e-cigarettes as a smoking 
cessation tool among current smokers with COPD in the US 
A: To estimate the 1-year and accumulated 5-year total healthcare cost savings 
associated with E-cigarettes (e-cigs) use in comparison to smoking cessation therapies 
among current smokers with COPD in the US 
B: To estimate the 1-year and accumulated 5-year total healthcare cost savings by 
gender associated with e-cigs use in comparison to smoking cessation therapies among 
current smokers with COPD in the US  
C: To estimate the 1-year and accumulated 5-year total healthcare cost savings by 
different age groups associated with e-cigs use in comparison to smoking cessation 
therapies among current smokers with COPD in the US  
Design: An epidemiological cohort-markov model was developed following the 
guidelines for Budget Impact Analysis—Principles of Good Practice: Report of the 
ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.99 
5.1: Methods 
Budget impact (BI) analysis is a type of pharmacoeconomic evaluation that is used to 
assess the changes in the healthcare spending when a new intervention is being 
adopted or implemented into the healthcare organization or system.99 The advantage of 
this methodology over other pharmacoeconomic evaluation techniques is that unlike 
cost-effectiveness (CE) or cost-benefit (CB) analysis which looks at a representative 
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individual or a cohort to estimate the cost and benefits associated with the new 
intervention, BI looks at the current and future population of interest and estimates the 
impact of introducing new intervention on short and long-term healthcare annual 
budgets.99 The primary purpose of BI analysis is to provide information on the impact of 
implementing a new technology on economic consequences into the current 
organizational system addressing questions related to affordability of the new 
intervention.99 The estimates for developing the BI model for this study were obtained 
from the publicly available data sources and published research studies. Below are the 
steps that were used to build the BI model following the guidelines as described by the 
ISPOR task force.  
Step 1: Characterizing the targeted population 
The targeted population represents the number of individuals who will be eligible to 
receive smoking cessation therapy before entering the BI model. To be eligible, the 
targeted cohort of participants should be residing in the US, been diagnosed with 
COPD, currently smoking cigarettes and have tried quitting smoking at least once in the 
past. Such a population was identified using the publicly available data sources as 
mentioned below: 
a) Current US population: The current US population data was obtained from the 
United States Census Bureau website.100 Adults of age 18 and above were only 
included for this study as it is illegal to sell or supply tobacco products to minors. The 
US population estimates were further stratified by different age groups and by gender in 
order to explore the differences in healthcare utilization and costs based on these 
factors.  
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b) COPD diagnosed population (prevalence and incidence):  Prevalence estimates 
for individuals diagnosed with COPD were obtained from the 2015 Behavioral Risk 
Factor Surveillance System (BRFSS) data. This cross-sectional survey is a federally 
funded telephone survey conducted annually by the CDC. It collects information from all 
50 states regarding modifiable risk factors for chronic diseases and other leading 
causes of deaths.101 It uses a multistage cluster design and random digit dialing to 
select a nationally representative sample of civilian, non-institutionalized adults aged 
≥18. The data from each state are weighted to reflect the respondent’s probability of 
selection and the age-by-sex or age-by-race/ethnicity-by-sex category in the population 
of the state.102 Since 2011, BRFSS uses only one question to assess COPD 
prevalence:  
 “Have you ever been diagnosed with chronic obstructive pulmonary disease, 
emphysema or chronic bronchitis?” 
Participants having answered yes to the above question were identified as having 
COPD. These estimates were also stratified by age and by gender. Prevalence 
estimates were calculated using BRFSS sample weights in order to represent the 
estimates at the national level and were obtained by using SAS version 9.4. The 
BRFSS data source was used in estimating COPD prevalence for the targeted 
population entering into the first year of the BI model. Starting from the second year, 
COPD incidence estimates were used in building the targeted population up to the 
period of 5-years. Incidence estimates for COPD were obtained from the report of 
several studies and surveys conducted by the CDC which estimated the new cases of 
COPD on the basis of the encounters from the emergency department visits and having 
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COPD as a first-listed diagnosis.103,104,105 The COPD incident case estimates that were 
considered in building the BI model are described in table 14 as below: 
Table 14: Incidence estimates for COPD in total, by gender and by age group 
status 
Variable 
Cases per 1000 
population 
Source 
Total 45.0 
Afonso et 
al., Mannino 
et al, Rycroft 
et al. 
Gender  
Male 46.8 
Female 43.4 
Age  
25–44 years 17.7 
44-65 years 39.1 
≥ 65 years 122.8 
 
c) Current smokers: 2015 BRFSS data source was used to estimate the percentages 
of current smokers among individuals with COPD. The BRFSS Survey captures this 
information by asking survey participants the following questions: 
 "Have you smoked at least 100 cigarettes in your entire life?"  
 "Do you now smoke cigarettes every day, some days, or not at all?"  
Participants having reported smoking at least 100 cigarettes in their lifetime and 
reporting currently smoking "every day" or "some days" were classified as current 
smokers. These estimates were also stratified by age and by gender and were obtained 
using SAS version 9.4. 
d) Have tried quitting smoking at least once in past one year:  The final step in 
identifying the targeted population was to obtain the percentages among current 
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smokers with COPD who wanted to quit smoking and had actually tried quitting at least 
once in the past one year. This represents the population who wants to quit smoking 
actively and are ready to try any of the smoking cessation therapies for quitting. These 
estimates were also obtained from 2015 BRFSS data, which asked participants the 
following survey question:  
 “During the past 12 months, have you stopped smoking for one day or longer because 
you were trying to quit smoking?”  
These estimates were further stratified by age and by gender. Figure 10 and Table 15 
below depicts the flow chart and represents the overall steps involved in obtaining the 
final targeted population. All our estimates were calculated using the BRFSS sampling 
weights and all our analysis were performed using SAS version 9.4. 
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Figure 10: Flowchart representing the steps involved in identifying the BI model targeted population 
Targeted population flowchart  
 
 
 
BRFSS 2015 estimates
US 2015 estimates
US Cesus bereau 
population
Have COPD
6.24%
Current smokers
35.38%
Have tried quitting 
smoking in past one 
year
63.36%
Haven't tried quitting 
smoking in past one 
year
36.64%Doesn't smoke 
currently 
64.62%
Don't have COPD
93.76%
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Table 15: Steps in identifying the targeted population for the BI model: analysis estimates using 2015 BRFSS 
data 
Targeted population Age group 
in years 
Male Female Total 
 US 2015 census 
estimates 
18-44  48.51% 58,511,002  45.17% 57,435,875           
247,773,709  45-64 34.00% 41,013,523  33.86% 43,052,457  
65 & above 17.49% 21,090,217  20.97% 26,670,635  
Total  100% 120,614,742 100% 127,158,967  
Age group in 
years  
BRFSS 2015       
estimates 
(%) 
Estimated 
population 
BRFSS 2015 
estimates (%) 
Estimated 
population 
Total 
Prevalence of COPD    6.24% 15,461,079  
Estimates by age and 
gender 
18-44  8.55% 1,321,922  10.63% 1,643,512             
15,461,079  45-64 17.66% 2,730,426  24.44% 3,778,687  
65 & above 16.60% 2,566,539  22.10% 3,416,898  
Total 42.81% 6,618,888  57.17% 8,839,099  
Percentage of current 
smokers among 
individuals with COPD  
  35.38% 5,470,129  
Estimates by age and 
gender 
18-44  11.24% 614,842  13.21% 722,604                
5,470,129  45-64 22.91% 1,253,206  31.13% 1,702,851  
65 & above 9.54% 521,850  11.96% 654,227  
Total 43.69% 2,389,899  56.30% 3,079,683  
Percentage of current 
smokers with COPD who 
have tried quitting 
smoking in past one year  
  63.36%                
 
 
 
3,465,874  Estimates by age and 
gender 
18-44  11.48% 397,882  14.65% 507,750  
45-64 21.99% 762,145  32.88% 1,139,579  
65 & above 7.97% 276,230  11.00% 381,246  
Total 41.44% 1,436,258.31  58.53% 2,028,576  
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Step 2: Selecting time horizon  
The BI model for this study was developed from the societal perspective for a period of 
5-years. Because of the short time period, healthcare costs in this model were not 
discounted.  
Step 3: Current and future treatment mix  
Following the guidelines for smoking cessation therapies from the United States Public 
Health Service, first-line agents recommended for smoking cessation are Varenicline, 
Bupropion and Nicotine Replacement Therapies (transdermal nicotine patch, nicotine 
gum, inhaler, lozenge, and/or nasal spray).57 These pharmacologic aids make it easier 
for a smoker to quit tobacco smoking by helping them in reducing the symptoms of 
nicotine withdrawal.60 Hence, the current treatment arm for this study consisted of the 
mix of these recommended pharmacotherapies along with their recommended dose and 
duration. Further, to this current treatment arm, e-cigs were added from the first year 
onwards until the period of 5-year as a future treatment mix. Additionally, we also 
compared e-cigs with no cessation alternative in order to evaluate the performance of e-
cig devices in the absence of any smoking cessation therapies and to estimate the total 
cost savings associated with its use in comparison to no cessation alternative. The 
detailed information for smoking cessation pharmacotherapies and e-cig devices 
included in the BI model are provided as below:  
Nicotine replacement therapy (NRT’s): NRT’s help in relieving nicotine withdrawal 
symptoms by providing nicotine to the smokers without using tobacco. Three types of 
NRT products that are currently available in the US without prescription includes 
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lozenges, gums and patch, while other two (nasal spray and oral inhaler) are available 
by prescription only.57 Long-acting nicotine patches are prescribed primarily to control 
long-term abstinence, while rapidly-acting nicotine lozenges/gums are provided to help 
relieve rapid acute cravings and withdrawal symptoms. The choice for this rapid-acting 
will depend on the patient comorbidities and their preferences.57 For this study, nicotine 
patches were considered as an option for smoking cessation in the BI model.  
Varenicline: In 2006, the Food and Drug Administration approved the use of 
Varenicline tartrate (Chantix) for its use in smoking cessation for the course of 12-weeks 
and is available only by prescription.106 It is a partial agonist at the alpha-4 beta-2 
subunit of the nicotine acetylcholine receptor where by binding to this receptor it helps in 
reducing the symptoms of nicotine withdrawal.107  It also blocks nicotine from the smoke 
to bind with this receptor and thereby reduces dependence on nicotine.  
Bupropion: Bupropion was approved by the Food and Drug Administration in 1997 as 
a smoking cessation pharmacotherapy drug that is available only by prescription. It 
exerts its main effect through blocking the reuptake of dopamine and noradrenaline with 
little serotonergic effect.108 It is available as an extended release anti-depressant pill 
that helps in reducing nicotine withdrawal symptoms. Treatment duration can be 
anywhere from 7 to 12 weeks long.  
E-cigarettes: There are over 400 brands of e-cigs and nearly 7000 unique flavors 
available for sale through internet.109 They are generally grouped into three categories: 
cigalikes, eGos and mods.110 Cigalikes resemble conventional cigarettes with respect to 
its shape and size. eGos are larger than cigalikes and have a removable tank to refill 
nicotine e-liquid. Mods are the largest e-cig devices that have batteries that can lasts 
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longer than the former two devices. Since Cigalikes claims to be a good substitute for 
smoking, are comparatively cheaper and healthier, and are effective for use in smoking 
cessation, this study mainly focused on Cigalikes e-cig brand for its use in smoking 
cessation.109  
Step 4: Determining efficacy  
Smoking cessation therapy outcome selected for this study was the carbon monoxide 
confirmed continuous smoking abstinence rate until 52-weeks. The annual abstinence 
rate reflects the rates for individuals who were compliant with the recommended dose 
throughout the treatment period and were able to be followed-up. Efficacy rates for 
Varenicline, Bupropion, and NRT’s were obtained from the published randomized 
controlled trials or meta-analyses studies. Rates for the e-cigs device were obtained by 
taking the average efficacy estimate from studies included in the literature review. The 
smoking cessation outcome considered in estimating the average efficacy estimate was 
continuous smoking abstinence among current smokers over the period of 12-months. 
We included 11 studies from the literature review that actually estimated smoking 
cessation outcome. The average smoking abstinence rate at 52-weeks for e-cigs device 
was estimated to be 21.08%(SD: 16.14; 95% CI: 11.94, 30.21), while the lower bound 
and upper bound values for the e-cigs efficacy were estimated to be 11.94% and 
30.21% respectively. Since the estimates came from different sources, sensitivity 
analysis were conducted over upper bound and lower bound efficacy estimates. The 
smoking cessation abstinence rates, therapy compliance rates, dose and duration for all 
pharmacotherapies and e-cig devices are provided in table 17. 
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Further, a markov model was developed that allowed individuals who failed to quit 
smoking in the first year to be given a further chance to quit smoking. A maximum of 
three quit attempts were allowed during a 5-year period.111 Also, for those who were 
successful in quitting smoking, a relapse rate of 10% was assumed.112 Hence, a cohort 
starting from the second year included both the population who failed to quit smoking in 
the previous year and the population who relapsed to smoking after successful quit 
attempt. This process was repeated for the next year until the end of 5-year period. The 
markov model structure that was used in this study is depicted in figure 11 as below: 
Figure 11: Markov model structure depicting the process of quitting among 
smokers  
Success 
Failure 
Quit attempt Smoking status
Relapse 
 
 
Step 5: Obtaining the market uptake rates  
Market shares for current smoking cessation drugs and the e-cigs device were obtained 
from a published market analysis research report.113 According to the report, the 
smoking cessation and nicotine de-addiction market is divided into three main 
components, which consists of drug therapy, NRT’s, and e-cigs. Drug therapy 
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comprises of the prescribed smoking cessation products such as Varenicline and 
Bupropion. The revenues generated from the sale of the smoking cessation and 
nicotine de-addiction products were estimated to be $2,600 million dollars for the year of 
2015. This report forecasted the future market shares for e-cigs and other smoking 
cessation alternatives up to the year 2024. Results indicated that smoking cessation 
market is going to expand and increase over the next few years where e-cig devices are 
going to possess a large market share in comparison to the drug therapies and NRT’s. 
For this study’s purpose, the market share for each alternatives were calculated in the 
form of percentages from the forecasted sales. The market uptake rates for e-cig 
devices in smoking cessation were considered from the years 2013 until the year 2017. 
Table 16 below contains the information related to market share dynamics for the 
smoking cessation alternatives in each of the 5-years of the model.  
Table 16: Market place dynamics for smoking cessation therapies in each of the 5 
years of the model113 
Year   NRT's (%) 
Drug therapies 
(Varenicline and 
Bupropion) (%) 
E-cigarettes (%) 
2013 40.91 13.64 45.45 
2014 44.00 8.00 48.00 
2015 42.86 10.71 46.43 
2016 41.94 9.68 48.39 
2017 42.86 8.57 48.57 
 
Step 6: Determining drug costs  
As the study was conducted from the societal perspective, drug retail prices were being 
evaluated. For Varenicline, we assumed the 12-week course treatment dosed at 1mg 
pill per day and the total costs for the smoking cessation treatment to be $567.82. For 
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Bupropion, we assumed 12-week course treatment dosed at 200 mg pill per day and 
the total cost for the smoking cessation treatment to be $191.76. Both Varenicline and 
Bupropion retail prices were obtained from rxprice.com. Additionally, a one-time 
physician visit cost for both of these prescription drugs was included and obtained from 
the healthcare blue book. For NRT’s, we assumed the 8-week course treatment of 
Nicoderm CQ patches. For individuals starting with Nicoderm CQ patches, we assumed 
a first two weeks treatment with 21 mg nicotine clear patches, followed by two weeks 
treatment with 14 mg nicotine clear patches and then by two weeks treatment with 7 mg 
nicotine clear patches. NRT’s retail pricing were obtained from drugstore.com. The total 
price for all the three prescription medications were calculated by multiplying per day 
dose cost with total duration. For e-cigarettes, the average price for Cigalikes brand 
were obtained through online websites. The average price of e-cigs from the five top 
selling brands were being considered for this study. Table 17 below details information 
on dose, duration, cost, compliance and efficacy rates for the smoking cessation 
alternatives considered for this study.  
Table 17: Information on dose, duration, cost, compliance and efficacy rates for 
the smoking cessation alternatives considered in the BI model 
Smoking-cessation 
treatment alternatives 
Value Source 
Varenicline114,115,116,117,118,
119 
  
Dose  1 mg/day 
Fiore MC, Ebbert JO 
Duration  12 weeks 
Smoking abstinence rate 
at 52-weeks; % (SD) 
22.5 (4.88) 
Taylor et al., Gonzales et al., 
Jorenby DE et al. 
Product compliance  84% Tashkin DP et al 
Cost of therapy 
 
Drug cost  
 
$827.85 
 
$567.85 
 
 
 
Rxprice.com 
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Physician visit cost  $260  Healthcare blue book 
Bupropion116,117,118,119   
Dose  200 mg once daily  
Taylor et al., Gonzales et al., 
Jorenby DE et al. 
Duration  12 weeks 
Smoking abstinence rate 
at 52-weeks; % (SD) 
15.7 (3.01) 
Product compliance 66% Tashkin D et al 
Cost of therapy 
 
Drug cost 
 
Physician visit cost  
$383.52 
                                     
$191.76 
 
$260 
 
 
Rxprice.com 
 
Healthcare blue book 
NRT 
(patch)114,116,117,120,121,122 
  
Dose  
Step 1: 21 mg patch/day 
for two weeks; step 2: 
14 mg patch/day for two 
weeks; step 3: 7 mg 
patch/day for two weeks 
Fiore MC et al., 2008 
 
Duration  8 weeks Fiore MC et al., 2008 
Smoking abstinence rate 
at 52-weeks; % (SD) 
15.5 (0.79) 
Taylor et al., Silagy C et al., 
Gonzales et al., Woolacott NF 
et al. 
Product compliance 78% Tonnesen P et al 
Cost of therapy 
                                  
                       $155  
Drugstore.com 
E-cigarettes 123,124   
Dose  
16 mg nicotine e-
cigarettes from one 
week before until 12 
weeks after quit day 
Bullen C et al. 
Duration  12 weeks Bullen C et al. 
Smoking abstinence rate 
at 52-weeks; % (SD) 
21.08(16.03) Literature review 
Product compliance 78% Bullen C et al. 
Cost of therapy $478.2 
http://ecigarettereviewed.com/
v2-cigs-e-cigarette-savings-
calculator/ 
No cessation116   
Smoking abstinence rate 
at 52-weeks; % (SD) 
5.0 (0.50) Taylor et al. 
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Step 7: Determining disease related costs  
The COPD disease related costs for current smokers were calculated by estimating the 
average per patient costs to treat COPD. As we were interested in learning about 
economic healthcare impact that these therapies will have from a societal perspective, 
both direct and indirect costs were calculated from the nationalized data. Results from 
the chapter 4 were used in developing the budget impact model. The healthcare costs 
used in the BI model were the incremental cost among current smokers with COPD in 
comparison to non-smokers. The cost estimates used were total costs, as well the costs 
by gender and by different age groups. Table 18 below provides the cost estimates that 
went into the BI model analysis. 
Table 18: Incremental cost among current smokers with COPD; estimates by 
total, by gender and by different age groups. 
COPD disease related 
costs 
Incremental cost 
Total incremental cost among 
current smokers with COPD 
 
$1,811 
Total incremental cost among 
current smokers with COPD 
by gender 
Male 
Female 
 
 
 
$1,687 
$1,915 
Total incremental cost among 
current smokers with COPD 
by age group 
18-44 
45-64 
65 & above 
 
 
 
$1,353 
$1,878 
$2,113 
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Step 8: Outcome evaluation  
BI outcomes evaluated were the total cost offset or cost savings associated with e-cigs 
use in comparison to smoking cessation alternatives and no cessation over the period 
of 1-year and 5-years. Further, we also evaluated the impact of age and gender on the 
BI model outcomes. Hence, three separate models were built in order to study the 
impact of e-cigs adoption among current smokers with COPD in overall population, by 
different age groups and by gender. For each year, the economic impact of using e-cigs 
as a smoking cessation tool over other available alternatives were obtained by 
multiplying the estimated number of COPD patients who effectively stopped smoking for 
the entire 1-year period by per person incremental healthcare costs which included 
both; drug therapy cost and COPD healthcare cost.  
Step 9: Model assumptions  
BI model for this study had the following model assumptions:  
 The final targeted population who have tried quitting smoking in the past represents 
the current US smoking population who wants to actively quit smoking  
 Smoking cessation rates reflects the successful quit attempt amongst users who were 
adherent to the therapy for at least 1 year and were able to follow up till end of the study  
 We assumed that smoking cessation rates for all of the pharmacotherapies/device 
observed in the controlled clinical trials were very similar to the real world scenario 
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  We also assumed that smoking cessation rates among COPD patient population 
were nearly similar to the smoking cessation rates observed in general healthy 
population in controlled clinical trials who wanted to quit smoking actively 
 All e-cig users who were allotted cigalikes for quitting smoking contained nicotine  
 Age and gender specific smoking cessation rates were assumed to remain constant 
throughout the 1-year period  
Step 10: Uncertainty analysis 
 In order to test for uncertainty associated with the model parameter estimates and 
model assumptions, one-way sensitivity analysis was performed on the following model 
parameters with the following ranges:  
 COPD incidence rate (3% - 6%) 
 COPD prevalence rate (3.1% - 12.3%) 
 Percentages of current smokers among COPD (22.22% - 44.55%) 
 Population who wants to quit smoking (51.47% - 75.35%) 
 E-cigs efficacy (11.94% - 30.21%) 
 E-cigs product cost ($216 - $740) 
 Product compliance for E-cigs (± 20%) 
 Product compliance for drug therapies (± 20%) 
 Product compliance for NRT’s (± 20%) 
 One additional physician visit for drug therapies ($260) 
 COPD healthcare cost ($345.47 - $3,277.93) 
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 Relapse rate (5% - 17%) 
Lower bound and upper bound values were considered for all the parameters in the 
sensitivity analysis. For those parameters whose upper bounds and lower bounds 
weren’t available, we changed the parameter estimates within the range of ± 20%. 
5.2: Results  
Aim 3A: To estimate the 1-year and accumulated 5-year total healthcare cost 
savings associated with E-cigarettes (e-cigs) use in comparison to smoking 
cessation therapies among current smokers with COPD in the US 
The total targeted population for the first year of the BI model was estimated to be 
3,460,976 and represented the individuals residing in the US, been diagnosed with 
COPD, currently smoking cigarettes and have tried quitting smoking in the past. This 
estimate represents the population who wants to quit smoking actively and are 
interested in trying any of the smoking cessation alternatives. The total number of 
successful quitters for all of the smoking cessation alternatives for the first year and the 
fifth year of the BI model were estimated to be around 497,446 and 316,325 
respectively. The accumulated 5-year success in achieving smoking abstinence were 
estimated to be 3,757,549 (20% of the total targeted population) for all of smoking 
cessation alternatives. The number of successful quitters were higher among e-cig 
users in comparison to those using drug therapies, NRT’s and no cessation. The 
number of successful quitters among e-cig users were higher by 19,835 for the 1st year, 
76,380 for 2nd year, 63,571 for 3rd year, 122,910 for 4th year, and 34,645 for 5th year 
in comparison to drug therapies and NRT's. The accumulated 5-year success in 
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achieving smoking abstinence among e-cig users were higher by 317,342 in 
comparison to drug therapies and NRT's. Total number of population who failed to quit 
smoking among e-cig users were lower by 404,452 and by 161,339 during the 1st year 
and 5th year of the BI model respectively in comparison to drug therapies and NRT's. 
The accumulated 5-year smoking cessation failure among e-cig users were lower by 
1,668,389 in comparison to drug therapies and NRT's. The adoption of e-cigs as a 
smoking cessation tool among COPD population over drug therapies and NRT’s can 
lead to the total healthcare loss of $20.10 million for the 1st year, savings of $17.85 
million for the 2nd year, loss of $17.33 million for the 3rd year, savings of $44.36 million 
for the 4th year and savings of $12.92 million for the 5th year. The accumulated 5-year 
total healthcare cost savings associated with the use of e-cigs over drug therapies and 
NRT's was estimated to be around $37.71 million. The adoption of e-cigs as a smoking 
cessation tool in comparison to no cessation alternative among COPD population can 
lead to the total healthcare cost savings of $20.10 million for the 1st year, $45.44 million 
for the 2nd year, $5.11 million for the 3rd year, and $30.06 million for the 5th year. The 
accumulated 5-year total healthcare cost savings associated with the use of e-cigs in 
comparison to no cessation alternative were estimated to be around $76.36 million. The 
BI model estimates for the adoption of e-cigs as a smoking cessation tool over other 
alternatives among COPD individuals in the US are provided in the table 19 as below. 
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Table 19: Budget Impact model for adopting e-cigs as a smoking cessation tool among current smokers with 
COPD; cost savings estimates over the period of 5-year 
BI model parameters First year Second year Third year Fourth year Fifth year 
General US population 247,773,709      
Prevalence of COPD 15,461,079          
Incident COPD population  10,454,068  9,983,635  9,534,371  9,105,324  
Percentage of current smokers 
among individuals with COPD  
5,462,399  3,693,422  3,527,218  3,368,493  3,216,911  
Percentage of current smokers with 
COPD who have tried quitting 
smoking in past one year  
3,460,976  2,340,152  2,234,845  2,134,277 2,038,235  
Total target population 3,460,976  5,353,426  6,923,261  8,198,003  2,197,388  
Market share estimates for smoking cessation alternatives 
Drug therapies 472,077.16  428,274.12  741,481.25  793,566.78  188,316  
NRT’s 1,415,885.38  2,355,507.67  2,967,309.67  3,438,242.85  941,800  
E-cigs 1,573,013.70  2,569,644.73  3,214,470.09  3,967,014.11  1,067,271  
No Cessation 3,460,976.24  5,353,426.51  6,923,261.02  8,198,003.95  2,197,388  
Number of successful quitters per year  
Drug therapies 67,625  61,350  106,217  113,678  26,976  
NRT’s 171,180  284,780  358,747  415,683  113,863  
E-cigs 258,641  422,511  528,536  652,272  175,485  
No Cessation 173,048  267,671  346,163 409,900  109,869  
Differences in the number of successful quitters between e-cig users and other smoking cessation alternatives 
 19,835 76,380  63,571  122,910  34,645  
Accumulated success 
 19,835 96,215  159,786  282,697  317,342  
Number of patients who failed to quit smoking per year 
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Drug therapy 404,452 366,923 635,264  679,888 161,339  
NRTs 1,244,704  2,070,726 2,608,561  3,022,559  827,936  
E-cigs 1,314,372  2,147,133  2,685,934  3,314,741  891,786  
                                      No cessation  3,287,927  5,085,755  6,577,097  7,788,103  2,087,519  
Differences in the number of failures between e-cig users and other smoking cessation alternatives 
 (334,784) (290,517) (557,891) (387,705) (97,490) 
Accumulated failures 
  (625,301) (1,183,193) (1,570,899) (1,668,389) 
Total healthcare costs savings associated with E-cigs use over other alternatives 
 ($20,101,088) $17,856,027 ($17,330,091) $44,362,032 $12,923,846 
Accumulated total healthcare cost savings over other alternatives 
  ($2,245,060) ($19,575,151) $24,786,880 $37,710,727 
Total healthcare costs savings associated with E-cigs use over no cessation 
 $20,101,088 $45,441,236 $5,111,387 ($4,257,479) $30,069,115 
Accumulated total healthcare costs savings associated with E-cigs use over no cessation 
  $76,766,835 $50,552,623 $46,295,144 $76,364,260 
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Aim 3B: To estimate the 1-year and accumulated 5-year total healthcare cost 
savings by gender associated with e-cigs use in comparison to smoking 
cessation therapies among current smokers with COPD in the US  
Two separate BI models were developed, one representing males and other 
representing females, in order to explore the differences in economic impact by gender 
for adopting e-cigs among current smokers with COPD.  
For the BI model representing males, the total targeted population for the first year of 
the model was estimated to be 1,436,258. The number of successful quitters were 
higher among e-cig users in comparison to those using drug therapies, NRT’s and no 
cessation. The number of successful quitters among e-cig users were higher by 8,231 
for the 1st year, 31,717 for 2nd year, 26,302 for 3rd year, 50,696 for 4th year, and 
14,119 for 5th year in comparison to drug therapies and NRT's. The accumulated 5-year 
success in achieving smoking abstinence among e-cig users were higher by 131,067 in 
comparison to drug therapies and NRT's. Total number of population who failed to quit 
smoking among e-cig users were lower by 138,931 and by 39,731 during the 1st year 
and 5th year of the BI model respectively in comparison to drug therapies and NRT's. 
The accumulated 5-year smoking cessation failure among e-cig users were lower by 
690,050 in comparison to drug therapies and NRT's. The adoption of e-cigs as a 
smoking cessation tool among COPD population over drug therapies and NRT’s can 
lead to the total healthcare loss of $9.36 million for the 1st year, savings of $3.48 million 
for the 2nd year, loss of $10.43 million for the 3rd year, savings of $12 million for the 4th 
year and savings of $3.51 million for the 5th year. The accumulated 5-year total 
healthcare cost loss associated with the use of e-cigs over drug therapies and NRT's 
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was estimated to be around $775,442 million. The BI model estimates for the adoption 
of e-cigs as a smoking cessation tool over other alternatives among COPD males in the 
US are provided in the table 20 as below. 
For the BI model representing females, the total targeted population for the first year of 
the model was estimated to be 2,028,576. The number of successful quitters were 
higher among e-cig users in comparison to those using drug therapies, NRT’s and no 
cessation. The number of successful quitters among e-cig users were higher by 11,626 
for the 1st year, 44,798 for 2nd year, 37,150 for 3rd year, 71,603 for 4th year, and 
19,942 for 5th year in comparison to drug therapies and NRT's. The accumulated 5-year 
success in achieving smoking abstinence among e-cig users were higher by 185,120 in 
comparison to drug therapies and NRT's. Total number of population who failed to quit 
smoking among e-cig users were lower by 196,226 and by 56,116 during the 1st year 
and 5th year of the BI model respectively in comparison to drug therapies and NRT's. 
The accumulated 5-year smoking cessation failure among e-cig users were lower by 
974,629 in comparison to drug therapies and NRT's. The adoption of e-cigs as a 
smoking cessation tool among COPD population over drug therapies and NRT’s can 
lead to the total healthcare loss of $10.57 million for the 1st year, savings of $15.13 
million for the 2nd year, loss of $6.25 million for the 3rd year, savings of $33.30 million for 
the 4th year and savings of $9.51 million for the 5th year. The accumulated 5-year total 
healthcare cost savings associated with the use of e-cigs over drug therapies and 
NRT's was estimated to be around $41.12 million. The BI model estimates for the 
adoption of e-cigs as a smoking cessation tool over other alternatives among COPD 
females in the US are provided in the table 21 as below. 
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The BI model estimates comparison among males and females informs that adoption of 
e-cigs as a smoking cessation tool can lead to higher success and lower failure rates in 
quitting smoking in comparison to drug therapies and NRT's. However, adoption of e-cig 
devices over the period of 5-year can lead to the loss in total healthcare among males, 
and can lead to substantial healthcare savings or gains among females. 
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Table 20: Budget Impact model for adopting e-cigs as a smoking cessation tool among males, currently smoking 
and with COPD; cost savings estimates over the period of 5-year 
 
BI model parameters for Males First year Second year Third year Fourth year Fifth year 
Total target population 1,436,258.31      
Market share estimates for smoking cessation alternatives 
Drug therapy 195,905.63  177,847.02  306,792.22  327,318.55  76,746.92  
NRTs 587,573.28  978,158.61  1,227,741.80  1,418,154.97  383,824.16  
E-cigs 652,779.40  1,067,082.12  1,330,005.87  1,636,254.62  434,958.92  
Number of successful quitters per year 
Drug therapy 28,063.48  25,476.59  43,947.99  46,888.38  10,994.00  
NRTs 71,037.61  118,259.38  148,433.98  171,454.94  46,404.34  
E-cigs 107,332.60  175,453.91  218,684.89  269,039.53  71,517.69  
Difference in the number of successful quitters between e-cig users and other smoking cessation alternatives 
 8,231 31,717  26,302  50,696  14,119  
Accumulated success 
                 39,949  66,252 116,948  131,067  
Number of patients who failed to quit smoking per year 
Drug therapy 167,842.15  152,370.43  262,844.24  280,430.17  65,752.92  
NRTs 516,535.67  859,899.23  1,079,307.81  1,246,700.03  337,419.82  
E-cigs 545,446.80  891,628.21  1,111,320.99  1,367,215.09  363,441.24  
Difference in the number of failures between e-cig users and other smoking cessation alternatives 
 (138,931) (120,641) (230,831) (159,915) (39,731) 
Accumulated failures 
  (259,572) (490,403) (650,318)                  (690,050)        
Average total healthcare cost  savings associated with E-cigs use over other alternatives 
 ($9,361,802.32) $3,484,199.82 ($10,430,121) $12,015,056.38 $3,517,224.85 
Accumulated total healthcare cost savings over other alternatives 
  ($5,877,602.50) ($16,307,723) ($4,292,667) ($775,442.31) 
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Table 21: Budget Impact model for adopting e-cigs as a smoking cessation tool among females, currently 
smoking and with COPD; cost savings estimates over the period of 5-year 
BI model parameters for Females First year Second year Third year Fourth year Fifth year 
Total target population 2,028,576      
Market share estimates for smoking cessation alternatives 
Drug therapy 276,697.80  251,191.75  433,314.40  462,305.86  108,397.62  
NRTs 829,890.54  1,381,554.62  1,734,066.78  2,003,007.00  542,114.58  
E-cigs 921,987.90  1,507,150.49  1,878,504.91  2,311,051.71  614,337.49  
Number of successful quitters per year 
Drug therapy 39,636.96  35,983.22  62,072.29  66,225.31  15,527.96  
NRTs 100,333.77  167,029.95  209,648.67  242,163.55  65,541.65  
E-cigs 151,596.94  247,811.71  308,871.29  379,992.37  101,011.83  
Difference in the number of successful quitters between e-cig users and other smoking cessation alternatives 
 11,626  44,798  37,150  71,603  19,942  
Accumulated success 
  56,424  93,575  165,178  185,120  
Number of patients who failed to quit smoking per year 
Drug therapy 237,060.84  215,208.53  371,242.11  396,080.55  92,869.66  
NRTs 729,556.77  1,214,524.66  1,524,418.11  1,760,843.46  476,572.92  
E-cigs 770,390.96  1,259,338.78  1,569,633.62  1,931,059.35  513,325.67  
Difference in the number of failures between e-cig users and other smoking cessation alternatives 
 (196,226) (170,394) (326,026) (225,864) (56,116) 
Accumulated failures 
  (366,621) (692,647) (918,512) (974,629) 
Average total healthcare cost  savings associated with E-cigs use over other alternatives 
 ($10,571,121.58) $15,138,030.43 ($6,258,886.26) $33,300,289.34 $9,515,842.36 
Accumulated total healthcare cost savings over other alternatives 
  $4,566,908.85 ($1,691,977.41) $31,608,311.93 $41,124,154.29 
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Aim 3C: To estimate the 1-year and accumulated 5-year total healthcare cost 
savings by different age groups associated with e-cigs use in comparison to 
smoking cessation therapies among current smokers with COPD in the US  
BI model was developed to estimate the economic impact of adopting e-cigs within 
different age groups; 18-44 years, 45-64 years, 65 & above. The total targeted 
population for the first year BI model were estimated to be 904,593 among individuals 
with 18-44 years, while for the individuals between 45-64 years and 65 & above, it was 
estimated to be around 1,902,765, and 658,516 respectively. The number of successful 
quitters were higher among e-cig users in comparison to those using drug therapies and 
NRT’s. The number of successful quitters during the 1st year of BI model were higher 
by 5,184 among individuals with 18-44 years, by 10,905 among individuals between 45-
64 years and by 3,774 among individuals with age 65 years and above. The number of 
successful quitters during the 5th year of BI model were higher by 7,875 among 
individuals with 18-44 years, by 16,566 among individuals between 45-64 years and by 
6,182 among individuals with age 65 years and above. The accumulated 5-year 
success in quitting smoking among e-cig users in comparison to drug therapies and 
NRT's were higher by 79,303 among individuals with 18-44 years, by 166,811 among 
individuals between 45-64 years and by 93,597 among individuals with age 65 years 
and above. The success in quitting were higher among 45-64 years of age group in 
comparison to individuals between 18 and 44 years and 65 & above years. Further, the 
number of individuals failing to quit smoking per year among e-cig users were lower in 
comparison to drug therapies and NRT's. The accumulated 5-year failure in quitting 
smoking among e-cig users were lower by 421,786 among individuals with 18-44 years, 
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by 887,206 among individuals between 45-64 years and by 452,652 among individuals 
with age 65 years and above. The failure rates were lower among individuals between 
45-64 years in comparison to individuals with 18-44 years and 65 & above age group. 
The adoption of e-cigs as a smoking cessation tool among COPD individuals between 
18 and 44 years of age group can lead to the loss of $7.6 million for the 1st year, $4.41 
million for the 2nd year, $11.74 million for 3rd year, $2.9 million for 4th year, and $0.66 
million for the 5th year. The adoption of e-cigs as a smoking cessation tool among 
COPD individuals between 45 and 64 years of age group can lead to the loss of $10.31 
million for the 1st year, savings of $12.49 million for the 2nd year, loss of $6.92 million for 
3rd year, savings of $27.46 million for 4th year, and savings of $7.31 million for the 5th 
year. The adoption of e-cigs as a smoking cessation tool among COPD individuals with 
age 65 & above can lead to the loss of $2.68 million for the 1st year, savings of $7.69 
million for the 2nd year, savings of $0.52 million for 3rd year, savings of $34 million for 4th 
year, and savings of $4.17 million for the 5th year.  The accumulated 5-year total 
healthcare cost savings associated with e-cigs use in comparison to drug therapies and 
NRT's were found to be $34.76 million and $38 million among COPD  individuals 
between 45-64 years and 65 & above respectively. Adoption of e-cigs among 
individuals with 18-44 years of age group would lead to a loss of $3.61 million in total 
healthcare costs over the period of 5-years. BI model estimates among different age 
groups for the adoption of e-cigs as a smoking cessation tool in presence of other 
smoking cessation alternatives are given in table 22 as below. 
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Table 22: Budget Impact model for adopting e-cigs as a smoking cessation tool among different age groups, 
currently smoking and with COPD; cost savings estimates over the period of 5-year 
BI model parameters 
by different age groups 
First year Second year Third year Fourth year Fifth year 
Total target population 
18-44  904,593.19      
45-64 1,902,765.00      
65 & above 658,516.12      
Number of patients quitting smoking per year  
Drug therapies                                                                                                                                                                             
18-44  17,675.12  15,829.93  26,860.34  28,171.56  6,132.52  
45-64 37,178.70  33,297.43  56,499.33  59,257.42  12,899.44  
65 & above 12,866.94  11,523.70  29,248.46  47,899.48  4,813.83  
NRT’s                                                                                                                       
18-44  44,741.35  73,480.69  90,720.58  103,013.86  25,884.64  
45-64 94,111.12  154,562.84  190,826.04  216,684.32  54,447.00  
65 & above 32,570.33  53,491.69  98,786.44  175,152.18  20,318.58  
E-cigs                                                                                                                           
18-44  67,600.89  109,018.63  133,656.85  161,644.80  39,893.02  
45-64 142,194.98  229,315.05  281,140.28  340,011.49  83,912.91  
65 & above 49,211.38  79,362.22  145,540.13  274,841.09  31,314.70  
Difference in the number of successful quitters between e-cig users and other smoking cessation alternatives  
18-44  5,184  19,708  16,075  30,459  7,875  
45-64 10,905  41,454  33,814  64,069  16,566  
65 & above 3,774  14,346  17,505  51,789  6,182  
Number of patients failing to quit smoking per year  
Drug therapies      
18-44  105,711  94,675  160,646  168,488  36,677  
45-64 222,358  199,145  337,911  354,406  77,149  
65 & above 76,954  68,920  174,929  286,477  28,790  
NRT’s      
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18-44  325,327  534,300  659,656  749,044  188,214  
45-64 684,310  1,123,872  1,387,553  1,575,576  395,900  
65 & above 236,828  388,954  718,305  1,273,583  147,742  
E-cigs      
18-44  343,536  554,014  679,222  821,452  202,729  
45-64 722,611  1,165,341  1,428,709  1,727,883  426,431  
65 & above 250,084  403,305  739,611  1,396,697  159,136  
Difference in the number of failures between e-cig users and other smoking cessation alternatives  
18-44  (87,502) (74,960) (141,080) (96,080) (22,162) 
45-64 (184,056) (157,676) (296,755) (202,100) (46,617) 
65 & above (63,699) (54,569) (153,623) (163,363) (17,396) 
Total healthcare cost savings with E-cigs use over other alternatives 
18-44  (7,626,718.21) (4,413,047.67) (11,740,412.76) (2,947,552.83) (666,804.14) 
45-64 (10,312,835.69) 12,497,723.17  (6,928,998.49) 27,462,219.50  7,301,435.56  
65 & above (2,682,305.10) 7,696,333.29  526,214.66  34,367,464.79  4,177,410.13  
Accumulated total healthcare cost savings with E-cigs use over other alternatives 
18-44   (4,413,047.67) (11,740,412.76) (2,947,552.83) (3,614,356.97) 
45-64  12,497,723.17  (6,928,998.49) 27,462,219.50  34,763,655.07  
65 & above  7,696,333.29  526,214.66  34,367,464.79  38,544,874.92  
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One-way sensitivity analysis results: 
One-way sensitivity analyses were performed on several of the model parameters. 
Table 23 below represents the sensitivity analysis estimates in terms of lower bound 
and upper bound for the parameters varied. The results indicate that e-cigs efficacy was 
the parameter with the highest influence on the BI model results, followed by cost for e-
cigs devices, product compliance for e-cigs, COPD healthcare cost and NRT’s product 
compliance. The parameters with minimal influence on the BI model results were drug 
therapies product compliance, additional physician visit cost, COPD incidence rate, 
prevalence of smoking among COPD individuals, population who wants to quit smoking, 
COPD prevalence rate and smoking relapse rate. A tornado diagram (Figure 12) was 
developed to display the one-way sensitivity analysis estimates for the varied 
parameters from most sensitive (bottom) to least sensitive (upper) parameters. The 
sensitive variable was changed at an uncertain value while all other variables were held 
constant at their baseline values. Green bars in figure 12 represent lower bound values, 
while blue bars represent upper bound values.  
Table 23: One-way sensitivity analysis results for the BI model 
5-year accumulated total healthcare cost savings among e-cig users in 
comparison to drug therapies and NRT’s among COPD individuals in the US  
Parameters varied One-way 
sensitivity analysis 
range  
Sensitivity analysis 
results (in millions) 
 Lower 
bound  
Upper 
bound 
Lower 
bound  
Upper 
bound 
E-cigs efficacy 11.94 30.21 -$1,173.00 $1,178.00 
E-cigs cost 216 740 $572.00 -$496 
E-cigs product compliance  63 93 -$490.00 $552 
COPD healthcare cost 345 3277 $427.00 $503 
NRT's product compliance  63 93 $470.00 -$387 
Drug therapy product compliance  60 90 $128.00 $53 
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One additional physician visit for drug 
therapy 
 899.8 -- $148 
COPD incidence rate 3 6 $25.00 $50 
Prevalence of smoking among COPD 22.22 44.55 $24.00 $48 
Population who wants to quit 
smoking 
51.47 75.35 $31.00 $45 
COPD prevalence rate 3.1 12.3 $41.00 $31 
Smoking relapse rate 5 17 $37.00 $39 
 
Figure 12: Tornado chart depicting the 5-year accumulated total healthcare cost 
savings among e-cig users in comparison to drug therapies and NRT’s among 
COPD individuals in the US. (Base case: $37.71 million) 
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5.3: Discussion 
This study analyzed the economic impact of adopting e-cigarettes as a smoking 
cessation tool among COPD patient population. For the first year of our BI model, we 
identified targeted population of around 3.5 million individuals who were current 
smokers, have tried quitting smoking in the past and have been diagnosed with COPD 
in the US. Total number of patients who were able to quit smoking successfully using e-
cigs over the period of 5-year were around 2 million and the rate of success was higher 
by 317,342 individuals in comparison to drug therapies and NRT’s. Adoption of e-cig 
device for quitting smoking over the period of 5-year in the current US healthcare 
system can lead to the cost savings of $37.71 million in comparison to drug therapies 
and NRT’s, while it can lead to the cost savings of $76.36 million in comparison to no 
cessation option.  
Adoption of this device among women can have a positive impact on the healthcare 
budget as the total healthcare cost savings associated with e-cigs use in comparison to 
other smoking cessation options over the period of 5-year was $41.12 million. Among 
men, adoption of e-cigs device may have a negative impact on the healthcare budget as 
providers will have to spend additional $775,442 dollars to achieve success in quitting 
with the help of e-cigs. The differences in healthcare savings among gender may be 
due to the differences in estimates by gender for the prevalence of COPD, for current 
smoking activity and for those trying to quit smoking in the past. According to the 
BRFSS estimates for this study, the prevalence of COPD was higher by 14% among 
women in comparison to men. Similarly, the prevalence estimates for current smokers 
with COPD were higher by 12% among women in comparison to men. Further, 
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prevalence estimates for individuals having tried quitting smoking in the past were 
higher by 17% among women in comparison to men. In addition, research studies have 
found that over the past few years, prevalence for COPD among women have 
surpassed men. Further, rates of hospitalizations and mortality due to COPD, and 
tobacco use have increased in past few years among women in comparison to men.125 
Healthcare cost estimates among current smokers with COPD from the MEPS data 
analysis were found to be higher among women in comparison to men. The estimates 
were higher by $228 among women in comparison to men.  
Further, BI model estimates among COPD current smokers with different age groups 
were different. The number of successful quitters associated with e-cigs use in 
comparison to other smoking cessation alternatives were found higher among 
individuals between 45-64 years of age in comparison to individuals between 18-44 
years of age and with age 65 and above. Further, the number of failures associated with 
e-cigs use in comparison to other smoking cessation alternatives were found lower 
among individuals between 45-64 years of age in comparison to individuals between 
18-44 years of age and with age 65 and above. The adoption of e-cigs among all 
different age groups for the first year was found to have a negative impact of the 
budget, while for the second year; it was found to have a positive impact on the 
healthcare budget among individuals with age 45 and above. Adoption of these devices 
among individuals with age 65 and above will have a positive impact on the budget and 
will lead to the healthcare cost savings of $38.0 million. Similarly, adoption of these 
devices among individuals between age 45 and 64 will have a positive impact on the 
budget and will lead to the healthcare cost savings of $34.0 million. The positive impact 
 
 
141 
 
on healthcare budget among individuals with age 45 and above could be due the 
differences in the prevalence and incidence estimates for COPD, for current smoking, 
and for those trying to quit smoking in the past. In addition, the healthcare costs among 
current smokers with COPD were higher among individuals with age 45 and above in 
comparison to individuals between age 18 and 44 years.  
This study possess several strengths. It is the first to assess the economic impact of e-
cigs among COPD current smoking population. We compared e-cigs with the highly 
recommended and highly utilized pharmacotherapies such as Varenicline, Bupropion, 
and NRT’s. Also, the results from this study are generalizable, as the epidemiological 
cohort model was developed to identify the targeted population. The cohort for the first 
year BI model included the COPD prevalent population analyzed using BRFSS 
database, while the cohort starting from the second year included incident population 
where the estimates came from the survey report conducted by the CDC. Further, a 
flexible BI model was developed for the purpose of creating estimates that can include 
several combinations of social service, healthcare, and other costs, contingent on the 
perspective.  
This study has a few limitations. First, because of the nature of the study design, BI 
model results were based on several assumptions. Because of the lack of randomized 
controlled trials for e-cigs in cessation among COPD patient population, all our smoking 
cessation estimates came from the general population, which could be the mix of 
healthy and unhealthy individuals. However, estimates for the targeted cohort were 
generalizable as they were analyzed using nationally representative sample from 
BRFSS data. Second, all the data estimates for the BI model were from the publicly 
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available information. Information on market share for smoking cessation, smoking 
cessation product prices and efficacy, incidence rates for COPD, relapse rate after 
quitting smoking were obtained from the published resources that were available online. 
However, to test uncertainty associated with these parameters and to estimate their 
impact on the BI model results, we conducted one-way sensitivity analysis on these 
parameters. Third, the BI model was developed only for a short-term period of 5 years 
due to the limitations associated with the data available for use. Fourth, smoking 
cessation outcomes evaluated were limited only up to the period of 1-year or 52-weeks. 
Evaluation of smoking abstinence for long-term will give a complete idea on the impact 
of adoption of e-cigs for smoking cessation into the current healthcare system. Finally, 
side effects associated with the use of e-cigs or other smoking cessation 
pharmacotherapies were not included in BI model estimates. Calculating the economic 
costs associated with the side effects of these smoking cessation options may have a 
different impact on the estimates for BI.  
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Chapter 6: Conclusions and Future research 
Conclusions: 
Our study estimated the economic impact of adopting e-cigarettes as a smoking 
cessation tool among current smokers with COPD. We conclude that implementing e-
cigs as a harm reduction tool among smokers with COPD can help them achieve 
smoking abstinence with a positive impact on the US healthcare budget. Adoption of 
these devices over the period of 5-year can lead to total healthcare costs savings of 
$37.71 million in comparison to other smoking cessation options such as Varenicline, 
Bupropion and NRT’s. Specifically, these devices will have higher healthcare cost 
savings among women and among individuals with age 65 & above. Overall, our study 
results indicate that use of these devices as a smoking cessation tool among diseased 
population such as COPD will have positive impact on patients and will be beneficial to 
the US healthcare budget.  
COPD is a progressive lung disease that possess a huge economic burden to the 
society. Tobacco smoking plays a key role to COPD development. The best way to 
avoid this disease development and reduce healthcare costs is to quit smoking. With 
the increase in awareness of e-cigs, these devices are being used an alternative to 
cigarette smoking or to help smokers in reducing or quitting cigarettes consumption. 
This study estimated the prevalence of current and ever e-cig users among COPD 
patient population using nationally representative US adult population. Prevalence of e-
cigs use was found to be higher among disease adult population in comparison to 
general healthy adult population. Popularity of electronic cigarettes have not just 
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increased in general population, but its demand and usage have also increased 
significantly among COPD disease population. Our results also suggest that among 
individuals with COPD, current e-cigs use was found to be higher among currently 
smoking population and among those who tried quitting the use of tobacco in past. 
These might suggests that these devices were either being tried as an alternative over 
other smoking cessation tools or were being used as a replacement to conventional 
cigarette smoking. However, evidences related to safety and efficacy for these devices 
still remains unknown, especially among COPD patient population. 
Future research: 
Based on the published evidences and nationally representative sample, this study 
supports the use of e-cigs in smoking cessation among COPD patient population. 
However, due to high uncertainty associated with the short- and long-term safety of 
these devices, we weren’t able to include them in our study. Hence, future studies are 
needed that can incorporate side-effects and safety associated with the use of these 
devices. Further, randomized controlled trials and cohort studies have evaluated the 
effectiveness of e-cigs for smoking cessation among healthy adult population. Research 
studies are needed that can evaluate the effectiveness of these devices among disease 
population such as COPD where quitting tobacco use is highly recommended 
alternative. Having clarity on side-effects, long-term and short-term safety and 
effectiveness of e-cigs use among COPD patient population will give more precise 
estimates for the adoption of these devices in US healthcare system. Further, these 
study assumed the use and effect of first generation e-cigs device among COPD 
individuals. Future studies are warranted that can compare the economic impact of first 
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generation with second, third and fourth generation e-cig devices. Additionally, the 
effect of FDA regulations on the perception and uptake of e-cigs device among 
diseased population are needed to help payers, clinicians and patients make informed 
decisions.  
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